=> d ibib abs hitstr l30 1-4

L30 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:197917 HCAPLUS
DOCUMENT NUMBER: 138:231736
TITLE: Inhibitors of **epoxide hydrolases** for the treatment of **hypertension**
INVENTOR(S): Kroetz, Deanna L.; Zeldin, Darryl C.; Hammock, Bruce D.; Morisseau, Christophe
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: U.S., 36 pp., Cont.-in-part of U.S. 6,150,415.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6531506	B1	20030311	US 2000-721261		20001121	<--
US 5955496	A	19990921	US 1997-909523		19970812	
US 6150415	A	20001121	US 1999-252148		19990218	<--
US 2003119900	A1	20030626	US 2002-328495		20021223	
US 6693130	B2	20040217				
US 2004092487	A1	20040513	US 2003-694641		20031027	
PRIORITY APPLN. INFO.:			US 1996-23397P	P	19960813	<--
			US 1997-909523	A2	19970812	<--
			US 1999-252148	A2	19990218	
			US 2000-721261	A1	20001121	
			US 2002-328495	A1	20021223	

OTHER SOURCE(S): MARPAT 138:231736
GI



I

AB The invention provides compds. that inhibit **epoxide hydrolase** in therapeutic applications for the treatment of **hypertension**. A preferred class of compds. for practicing the invention have the structure shown by Formula [(R1)(R2)XW(Z)Y(R3)(R4)], wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

IT **7570-86-7 27729-98-2 82389-34-2 204922-97-4 501004-12-2 501004-13-3 501004-17-7 501004-18-8 501004-19-9 501004-20-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**epoxide hydrolases** inhibitors for treatment of

hypertension)

RN 7570-86-7 HCAPLUS
CN Methanone, phenyl[(2R,3S)-3-phenyloxiranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 27729-98-2 HCAPLUS
CN Methanone, [(2R,3S)-3-(4-fluorophenyl)oxiranyl]phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 82389-34-2 HCAPLUS
CN Methanone, [(2R,3S)-3-[1,1'-biphenyl]-4-yloxiranyl]phenyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 204922-97-4 HCAPLUS
CN Oxiranemethanol, α,3-diphenyl-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-12-2 HCAPLUS
CN Oxiranemethanol, 3-(4-fluorophenyl)-α-phenyl-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-13-3 HCAPLUS
CN Oxiranemethanol, 3-[1,1'-biphenyl]-4-yl-α-phenyl-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-17-7 HCAPLUS
CN Methanone, [(2R,3S)-3-[1,1'-biphenyl]-4-yloxiranyl](4-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-18-8 HCAPLUS
CN Oxiranemethanol, 3-[1,1'-biphenyl]-4-yl-α-(4-methylphenyl)-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-19-9 HCAPLUS

CN Ethanone, 1-[(2R,3S)-3-(4-nitrophenyl)oxiranyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501004-20-2 HCAPLUS
CN Oxiranemethanol, α-methyl-3-(4-nitrophenyl)-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:443332 HCAPLUS
DOCUMENT NUMBER: 127:60620
TITLE: Inhibition of fatty acid synthase as a means to reduce adipocyte mass
INVENTOR(S): Kuhajda, Francis P.; Pasternack, Gary R.; Townsend, Craig A.; Mani, Neelakandha S.
PATENT ASSIGNEE(S): Johns Hopkins University, USA; Kuhajda, Francis P.; Pasternack, Gary R.; Townsend, Craig A.; Mani, Neelakandha S.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9718806	A1	19970529	WO 1996-US17678	19961115 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9676685	A1	19970611	AU 1996-76685	19961115 <--
EP 869784	A1	19981014	EP 1996-939542	19961115 <--
EP 869784	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 303144	E	20050915	AT 1996-939542	19961115 <--
PRIORITY APPLN. INFO.:			US 1995-6940P P	19951117 <--
			WO 1996-US17678 W	19961115 <--

OTHER SOURCE(S): MARPAT 127:60620

AB Weight loss was noted in nude mice treated with cerulenin, a non-competitive inhibitor of FAS. Sustained reduction of adipocyte mass in humans without toxicity would significantly impact disease prevention worldwide. Aside from psychol. and self-esteem improvement, weight loss via reduction of adipocyte mass may: (1) ameliorate hyperglycemia associated with non-insulin-dependent diabetes mellitus thereby reducing diabetic complications such as arterial disease, blindness, cataracts, etc., (2) reduce **hypertension**, (3) reduce risk of coronary artery vascular disease and stroke, and (4) reduce the risk of other complications of massive obesity such as osteoarthritis, surgical complications, etc. There is also potential use in livestock and poultry to reduce the saturated fat content of meat products. Therefore FAS inhibitors are disclosed herein as novel agents for weight reduction A family of compds. (γ-substituted-α-methylene-β-carboxy-γ-butyrolactones) whose synthesis was based on the cerulenin motif is shown herein to inhibit fatty acid synthesis, inhibit growth in certain susceptible tumor cells, and induce weight loss.

IT **17397-89-6**, Cerulenin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of fatty acid synthase as a means to reduce adipocyte mass)

RN 17397-89-6 HCAPLUS

CN Oxiranecarboxamide, 3-[(4E,7E)-1-oxo-4,7-nonadienyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L30 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1993:409168 HCAPLUS
DOCUMENT NUMBER:	119:9168
TITLE:	Preparation of oxiranyl and oxetanyl renin inhibiting compounds
INVENTOR(S):	Rosenberg, Saul H.
PATENT ASSIGNEE(S):	Abbott Laboratories, USA
SOURCE:	PCT Int. Appl., 168 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222313	A1	19921223	WO 1992-US4423	19920526 <--
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5258362	A	19931102	US 1992-880250	19920513 <--
AU 9221593	A1	19930112	AU 1992-21593	19920526 <--
PRIORITY APPLN. INFO.:			US 1991-713475 A	19910611 <--
			US 1992-880250 A	19920513 <--
			WO 1992-US4423 A	19920526 <--
OTHER SOURCE(S):	MARPAT 119:9168			

GI



I



II



III



V

AB The title compds. I and II [R = mimic of Phe-His dipeptide; R4 = lower alkyl, cycloalkyl, arylalkyl; R5 = H, lower alkyl, hydroxyalkyl, lower alkenyl, CHO; R6 = OH, NH2; R7 = H, lower alkyl; R8 = H, lower alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyalkyl, thioalkoxyalkyl, haloalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl, cycloalkylalkyl, lower alkenyl, alkynyl, aryl, arylalkyl, heterocyclic, heterocycloalkyl; R7R8 = (CH2)n, n = 3-6; R9 = lower alkyl] or a pharmaceutically acceptable salt, ester, or prodrug of, were prepared as renin inhibitors. Thus, Reformatskii reaction of (4S,5R)-3-tert-butoxycarbonyl-4-cyclohexylmethyl-2,2-dimethyloxazolidine-5-carboxaldehyde with benzyl bromoacetate gave hydroxy ester III (Boc = Me3CO2C; R1 = CO2CH2Ph), which was reduced with NaBH4-CaCl2 to diol III (R1 = CH2OH) and selectively tosylated to tosylate III (R1 = CH2O3SC6H4Me-4) (IV). Cyclization of tosylate IV to the corresponding oxetane, followed by acidic deprotection, coupling with Boc-Phe-His(Boc)-OH, and selective deblocking gave oxetanyl peptide V. Compds. I and II are useful in treating **hypertension**, congestive heart failure, glaucoma, and inhibiting HIV-1 and HIV-2 proteases.

IT **147896-98-8P 147977-61-5P 147977-62-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as renin inhibitor)

RN 147896-98-8 HCAPLUS

CN L-Leucinamide, N-(ethoxycarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-(3-ethyloxiranyl)-2-hydroxyethyl]-, [2S-[2α(1R*,2R*),3β]]- (9CI) (CA INDEX NAME)



RN 147977-61-5 HCAPLUS
CN L-Leucinamide, N-(ethoxycarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-(3-ethyloxiranyl)-2-hydroxyethyl]-, [2S-[2α(1R*,2R*),3α]]- (9CI) (CA INDEX NAME)



RN 147977-62-6 HCAPLUS
CN L-Leucinamide, N-(ethoxycarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-(3-ethyloxiranyl)-2-hydroxyethyl]-, [2R-[2α(1S*,2S*),3β]]- (9CI) (CA INDEX NAME)



L30 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1956:40198 HCAPLUS
DOCUMENT NUMBER: 50:40198
ORIGINAL REFERENCE NO.: 50:7731a-d
TITLE: Autoxidation of α,β-unsaturated ketones
AUTHOR(S): Hawkins, E. G. E.

CORPORATE SOURCE: Distillers Co., Ltd., Great Burgh, UK
SOURCE: Journal of the Chemical Society, Abstracts (**1955**) 3288-90
CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The effect of a carbonyl group upon the autoxidation of olefins was determined The rate of autoxidation of mesityl oxide (I) is greater than that of isophorone (II). I (137 g.) and 0.1 g. Co naphthenate with 17 l. O at about 100° for 9 3/4; hrs. gave 3.3 l. CO2, 3.9 g. Me2CO and AcH, and 143.7 g. of product, which (71 g.) gave on distillation 2.7 g. impure HOAc, 36.5 g. I, 8.5 g. impure 3,4-epoxy-4-methyl-2-pentanone (III), b. 155° (2,4-dinitrophenylhydrazone, m. 126-8°), 2.4 g. of a fraction b15 64-80°, possibly containing CH2:CMeCH(OH)Ac (IV) [bis-2,4-dinitrophenylhydrazone, m. 260° (decomposition)], 3.8 g. of a fraction (V) b15 80-110° containing IV, 5.0 g. of a fraction (VI) b15 110-40°, and 2.8 g. residue. Hydrolysis of V gave an unresolved mixture of acids and Me2C(OH)CH(OH)Ac (VII) (2,4-dinitrophenylhydrazone, m. 160-62°), while VI gave AcCH2CMeCO2H, m. 100-103° (from C6H6). CH2O and HCO2H have been detected. III was isomerized in an Al2O3 column to Me2CHCOAc, b. 100-20°; 2,4-dinitrophenylhydrazone, m. 115-17°; dioxime, m. 153-5°. II (150 g.), 10 g. MgO, 0.1 g. Co naphthenate, and 12 l. O at about 100° 24 hrs. gave CO2, 1 g. Me2CO and AcH, and 171.4 g. of product (VIII). Distillation of VIII after removal of Mg salts gave II, 3.8 g. impure 2,5,5-trimethyl-1,2-cyclohexanedione, b15 90-110° [bis(phenylhydrazone), m. 199-200°; bis(2,4-dinitrophenylhydrazone), m. 276-8°], and 8.1 g. viscous sirup containing esters. Acidification of the Mg salts with HCl and extraction with ether gave 1.2 g. HCO2H and HOAc, 5.1 g. HO2CCMe2CH2CO2H, b15 about 90°, m. 140-1° (from C6H6), 6.8 g. 5,5-dimethyl-3-oxo-1-cyclohexene-carboxylic acid (IX), m. 153-5° (from C6H6) (semicarbazone, m. 224-5° from EtOH; 2,4-dinitrophenylhydrazone, m. 211-12°), and 2,2-dimethylglutaric anhydride, m. 123-5°, which on hydrolysis gave 2,2-dimethylglutaric acid (X), m. 100-101.5°. Decomposition of the ozonide of IX gave X.

IT **4478-63-1**, 2-Pentanone, 3,4-epoxy-4-methyl-
(preparation of)

RN 4478-63-1 HCAPLUS

CN Ethanone, 1-(3,3-dimethyloxiranyl)- (9CI) (CA INDEX NAME)



RN 501004-09-7 HCAPLUS
CN Dodecanoic acid, 12-[[(2-naphthalenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:610408 HCAPLUS
DOCUMENT NUMBER: 137:154844
TITLE: Preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Wu, Chengde; Blok, Natalie; Patricia, Woodard Timothy; Keller, Karin; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 65 pp., Cont.-in-part of U.S. 6,248,767.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432994	B1	20020813	US 2000-403599	20000327 <--
US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926 <--
WO 9849162	A1	19981105	WO 1998-US6680	19980402 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2002091270	A1	20020711	US 2001-29561	20011220 <--
US 6683103	B2	20040127		

PRIORITY APPLN. INFO.:

US 1997-847797	A2	19970428 <--
US 1997-938444	A2	19970926 <--
WO 1998-US6680	W	19980402
US 2000-403599	A3	20000327

OTHER SOURCE(S): MARPAT 137:154844
GI



II

AB The title sulfonamides Ar2-SO2-NH-Ar1 [I; Ar1 = (un)substituted 5-6 membered heteroaryl; Ar2 = thienyl, furyl, pyrrolyl] and their pharmaceutically acceptable salts, useful for modulating or altering the activity of the endothelin family of peptides, were prepared and formulated. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, are provided. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presencé of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A solution of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II.

IT **184035-57-2P**, N-(4-Bromo-3-methyl-5-isoxazolyl)-2-[N'-(3,4-methylenedioxyphenyl)ureido]thiophene-3-sulfonamide **184035-67-4P**, N,N'-Bis[3-[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea **184035-68-5P**, N,N'-Bis[3-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)

RN 184035-57-2 HCAPLUS

CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-67-4 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-68-5 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 271 THERE ARE 271 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:534073 HCAPLUS
DOCUMENT NUMBER: 137:93741
TITLE: Preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivatives as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Blok, Natalie
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 59 pp., Cont.-in-part of U. S. 5,962,490. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6420567	B1	20020716	US 1997-938325	19970926 <--
US 5962490	A	19991005	US 1996-721183	19960927 <--
AU 9935803	A1	19990916	AU 1999-35803	19990622 <--
AU 726595	B2	20001116		
US 2002091272	A1	20020711	US 2001-11610	20011105 <--
US 6632829	B2	20031014		
US 2003208084	A1	20031106	US 2003-447763	20030528 <--
PRIORITY APPLN. INFO.:			US 1996-721183 A2	19960927 <--
			US 1987-100865 A2	19870925 <--
			US 1990-416199 A2	19900515 <--
			US 1993-65202 B2	19930520 <--
			US 1993-100125 B2	19930730 <--
			US 1993-100565 A2	19930730 <--
			US 1993-142159 A2	19931021 <--
			US 1993-142552 A2	19931021 <--
			US 1993-142631 B2	19931021 <--
			US 1994-222287 A2	19940405 <--
			US 1994-247072 A2	19940520 <--
			US 1995-417075 A2	19950404 <--
			US 1995-477223 A2	19950606 <--

AU 1996-55367	A	19960404 <--
WO 1996-US4759	A2	19960404 <--
US 1997-938325	A3	19970926 <--
US 2001-11610	A3	20011105

OTHER SOURCE(S): MARPAT 137:93741
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Thienyl-, furyl-, and pyrrolylsulfonamides, formulations of pharmaceutically acceptable salts thereof, and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, disclosures include N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; wherein Ar1 = (un)substituted monocyclic or polycyclic heteroaryl, particularly isoxazolyl; Ar2 = G1 or G2; M = (CH2)mCO(CH2)n, (CH2)mCONH(CH2)n, (CH2)mCH:CH(CH2)n, (CH2)mCO(CH2)pNH(CH2)n, C:N(OH)(CH2)n, (CH2)mCO(CH:CH)pNH(CH2)n,CH(OH)(CH2)n, CH(CH)CO(CH2)n, CH(CH3)CO(CH2)mCH:CH(CH2)n, (CH2)n, (CH2)nO, CH2SO0-2, or CO2; m, n, and p = independently 0-6; R1-R5 = independently H, OH, NO2, CN, halo, alkyl, alkenyl, alkynyl, (hetero)aryl, arylalkyl, alkylamino, alkylthio, haloalkyl, alkoxy, alkylsulfonyl, (un)substituted amino, carbamoyl, etc.; or 2 adjacent R1-R5 form alkylenedioxy, alkylenethioxyoxy, or alkylenedithioxy; with provisos; X = S, O, or NR11; R11 = H, (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, heterocyclyl, aralkyl, aralkoxy, alkylalkenyl, alkylalkynyl, OH, CN, acyl, acyloxy, carboxy, SH, NHOH, (un)substituted amino, carbamoyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include **hypertension**, cardiovascular disease, asthma, **hypertension**, inflammatory disease, glaucoma, etc. Twenty synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 3-cyanomethyl-2,4,6-trimethylaniline was treated with H2SO4 in MeOH to give Me 3-amino-2,4,6-trimethylphenylacetate (88%). Amidation with N-(4-chloro-3-methyl-5-isoxazolyl)-3-sulfamoylthiophene-2-carboxylic acid using 1,1'-carbonyldiimidazole in DMF afforded II (15%). The similarly prepared title compound III exhibited IC50 values of 0.0015 ± 0.0014 μM for ETA receptors and 0.324 ± 0.78 μM for ETB receptors. Claimed compds. also exhibited improved oral half-life, bioavailability, and/or in vivo activity over those disclosed previously.

IT **184035-57-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(endothelin modulator; preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivs. as endothelin activity modulators)

RN 184035-57-2 HCAPLUS

CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:241376 HCAPLUS
DOCUMENT NUMBER: 136:263162
TITLE: Preparation of 1-phenylimidazol-2-one biphenylmethyl compounds as angiotensin II receptor antagonists for treatment of circulatory disorders
INVENTOR(S): Reitz, David B.; Manning, Robert E.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont. of U. S. Ser. No. 625,770, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2002038035	A1	20020328	US 2001-825029	20010403	<--
US 6630497	B2	20031007			
EP 978515	A2	20000209	EP 1999-115158	19940308	<--
EP 978515	A3	20000517			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
US 2004048911	A1	20040311	US 2003-649210	20030827	
US 6858636	B2	20050222			

PRIORITY APPLN. INFO.:

US 1993-36316	B1	19930324 <--
US 1997-787841	B1	19970123 <--
US 1998-24021	B1	19980216
US 1999-239443	B1	19990128
US 1999-450926	B1	19991129
US 2000-625770	B1	20000726
EP 1994-912751	A3	19940308 <--
US 2001-825029	A1	20010403

OTHER SOURCE(S): MARPAT 136:263162
GI



I



II

AB The title angiotensin II receptor antagonists, e.g. I [R1, R2, R3 = H, alkyl, alkoxy, cyano, halo, hydroxy, carboxyl, alkoxycarbonyl, formyl, acetyl, alkylcarbonyl, haloalkylcarbonyl; R4 = H, Me, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxy and dimethoxymethyl; R5 = Me, Et, Pr, iso-Pr, Bu, sec-Bu, iso-Bu, tert-Bu, n-pentyl, isopentyl, neopentyl, Ph, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl; R6 = an acidic group, such as CO2H or tetrazolyl], were prepared for therapeutic use in the treatment of circulatory disorders, such as **hypertension** and congestive heart failure. Thus, imidazol-2-one II was prepared in 73% yield by condensation of N-triphenylmethyl-5-[4'-(bromomethyl)biphenyl-2-yl]tetrazole and 4-butyl-1-(2-ethylphenyl)-1,3-dihydro-2H-imidazol-2-one using tert-BuOK in THF and DMF. The prepared imidazoles were tested for angiotensin II receptor binding activity.

IT **169238-08-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-phenylimidazol-2-one biphenylmethyl compds. for treatment of circulatory disorders)

RN 169238-08-8 HCAPLUS

CN Hexanamide, 2-[[[(2-ethylphenyl)amino]carbonyl]amino]-N-methoxy-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 6 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:449271 HCAPLUS
DOCUMENT NUMBER: 135:46080
TITLE: Formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Blok, Natalie; Wu, Chengde; Woodard, Patricia; Keller, Karin; Kogan, Timothy
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: U.S., 58 pp., Cont.-in-part of U.S. 5,783,705.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6248767	B1	20010619	US 1997-938444	19970926 <--
US 5783705	A	19980721	US 1997-847797	19970428
CA 2281090	AA	19981105	CA 1998-2281090	19980402 <--
CA 2281090	C	20050607		
CA 2496680	AA	19981105	CA 1998-2496680	19980402 <--
WO 9849162	A1	19981105	WO 1998-US6680	19980402 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9869504	A1	19981124	AU 1998-69504	19980402 <--
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402 <--
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402 <--
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402 <--
TR 9902401	T2	20000821	TR 1999-9902401	19980402 <--
NZ 336898	A	20011026	NZ 1998-336898	19980402 <--
JP 2001520643	T2	20011030	JP 1998-540982	19980402 <--

JP 3455233	B2	20031014		
TR 200101905	T2	20020621	TR 2001-200101905	19980402 <--
TR 200202738	T2	20030321	TR 2002-200202738	19980402 <--
JP 2003176288	A2	20030624	JP 2002-352236	19980402 <--
EE 200300214	A	20030815	EE 2003-200300214	19980402 <--
SG 100766	A1	20031226	SG 2001-200106590	19980402 <--
SG 100767	A1	20031226	SG 2001-200106591	19980402 <--
IL 131318	A1	20040831	IL 1998-131318	19980402 <--
EP 1498418	A1	20050119	EP 2004-24998	19980402 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
EP 1498419	A1	20050119	EP 2004-24999	19980402 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
IL 156977	A1	20050320	IL 1998-156977	19980402 <--
AT 292129	E	20050415	AT 1998-915281	19980402 <--
ES 2241133	T3	20051016	ES 1998-915281	19980402 <--
NO 9905221	A	19991228	NO 1999-5221	19991026 <--
MX 9909860	A	20000331	MX 1999-9860	19991027 <--
US 6432994	B1	20020813	US 2000-403599	20000327 <--
HK 1028033	A1	20050506	HK 2000-107366	20001117 <--
US 2001039289	A1	20011108	US 2001-792237	20010223 <--
US 6458805	B2	20021001		
US 2002091270	A1	20020711	US 2001-29561	20011220 <--
US 6683103	B2	20040127		

PRIORITY APPLN. INFO.:	US 1997-847797	A2	19970428 <--
	US 1997-938444	A	19970926 <--
	CA 1998-2281090	A3	19980402
	EE 1999-469	A	19980402
	EP 1998-915281	A3	19980402
	IL 1998-131318	A3	19980402
	JP 1998-540982	A3	19980402
	WO 1998-US6680	W	19980402
	US 2000-403599	A3	20000327

OTHER SOURCE(S): MARPAT 135:46080

GI



II

AB Formulations of pharmaceutically acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations, are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and

N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor, by contacting the receptor with the sulfonamide salt, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamide salts or prodrugs thereof, that inhibit or increase the activity of endothelin, are also provided. In particular, pharmaceutically acceptable salts of compds. Ar2-SO2-NH-Ar1 [I; where Ar1 = 5-membered heteroaryl; Ar2 = thienyl or thionaphthyl; salt is with an alkali metal or mineral acid] are claimed. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presence of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A solution of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II.

IT **184035-57-2P**, N-(4-Bromo-3-methyl-5-isoxazolyl)-2-[N'-(3,4-methylenedioxyphenyl)ureido]thiophene-3-sulfonamide **184035-67-4P**, N,N'-Bis[3-[[3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea **184035-68-5P**, N,N'-Bis[3-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)

RN 184035-57-2 HCAPLUS
CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-67-4 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-68-5 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 219 THERE ARE 219 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:785898 HCAPLUS
DOCUMENT NUMBER: 133:329627
TITLE: Tetracyclic cGMP-specific phosphodiesterase inhibitors and their use in disease treatment
INVENTOR(S): Daugan, Alain Claude Marie; Gellibert, Francoise
PATENT ASSIGNEE(S): Icos Corp., USA
SOURCE: U.S., 30 pp., Cont.-in-part of PCT 9519978.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     US 6143746            A     20001107    US 1998-154051          19980916 <--
     WO 9519978            A1    19950727    WO 1995-EP183           19950119 <--
         W:  AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
             GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
             MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT,
             UA, US
         RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
             MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
             TD, TG
     WO 9703675            A1    19970206    WO 1996-EP3024          19960711 <--
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA
     WO 9703985            A1    19970206    WO 1996-EP3025          19960711 <--
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA
     US 6025494            A     20000215    US 1998-133078          19980812 <--
     CA 2340636            AA    20000323    CA 1999-2340636         19990826
     EP 1113800            A1    20010711    EP 1999-945201          19990826
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002524516         T2    20020806    JP 2000-569812          19990826
     US 6127542            A     20001003    US 1999-399667          19990921 <--
     US 6369059            B1    20020409    US 2000-633431          20000807 <--
     CZ 289832             B6    20020417    CZ 2000-3428            20000919 <--
     US 2002119976         A1    20020829    US 2002-68114           20020205 <--
     US 6784179            B2    20040831
     JP 2004217674         A2    20040805    JP 2004-125881          20040421 <--
PRIORITY APPLN. INFO.:                         GB 1994-1090        A   19940121 <--
                                               WO 1995-EP183       A2  19950119 <--
                                               GB 1995-14464       A   19950714 <--
                                               GB 1995-14465       A   19950714 <--
                                               WO 1996-EP3024      A2  19960711 <--
                                               WO 1996-EP3025      A2  19960711 <--
                                               JP 1995-519339      A3  19950119 <--
                                               CZ 1998-33          A3  19960711 <--
                                               US 1996-669389      A3  19960716 <--
                                               US 1998-133078      A1  19980812
                                               US 1998-154051      A   19980916
                                               WO 1999-US19466     W   19990826
                                               US 1999-399667      A1  19990921
                                               US 2000-633431      A1  20000807

OTHER SOURCE(S):         MARPAT 133:329627
GI
```



I

AB A compound of formula I (R0 = H, halogen, C1-6 alkyl; R1 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo-C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-3 alkyl, aryl-C1-3 alkyl, heteroaryl-C1-3 alkyl; R2 = (substituted) monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or (substituted) bicyclic ring (a) attached to the rest of the mol. via one of the benzene ring carbon atoms, and wherein the fused ring is a 5- or 6-membered ring which may be saturated or partially or fully unsatd., and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; R3 = H, C1-3 alkyl, or R1 and R3 together = 3- or 4-membered alkyl or alkenyl chain) and salts and solvates thereof is disclosed. Compound I is a potent and selective inhibitor of cyclic guanosine 3',5'-monophosphate-specific phosphodiesterase, having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction. Thus, many I compds. were synthesized and tested in vitro as inhibitors of cGMP phosphodiesterase. Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione showed IC50 of 10 nM.

IT **34262-84-5**, Mesocarb
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug containing phosphodiesterase inhibitor and; tetracyclic cyclic GMP-specific phosphodiesterase inhibitors and their use in disease treatment)

RN 34262-84-5 HCAPLUS

CN 1,2,3-Oxadiazolium, 3-(1-methyl-2-phenylethyl)-5-[[(phenylamino)carbonyl]amino]-, inner salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:323253 HCAPLUS
DOCUMENT NUMBER: 132:334655
TITLE: preparation of himbacine analogs as thrombin receptor antagonists
INVENTOR(S): Chackalamannil, Samuel; Asberom, Theodros; Xia, Yan; Doller, Dario; Clasby, Martin C.; Czarniecki, Michael

F.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 161 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6063847	A	20000516	US 1998-197442		19981123	<--
US 6326380	B1	20011204	US 2000-545720		20000407	<--
PRIORITY APPLN. INFO.:			US 1997-66518P	P	19971125	<--
			US 1998-197442	A3	19981123	

OTHER SOURCE(S): MARPAT 132:334655
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Heterocyclic-substituted tricyclics of the formula (I) [single dotted line represents an optional double bond; double dotted line represents an optional single bond; n = 0-2; Q =(un)substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het = (un)substituted mono-, bi- or tricyclic heteroarom. group; B = -(CH2)n3-, wherein n3 is 0-5, -CH2-O-, -CH2S-, -CH2-NR6-, -C(O)NR6-. -NR6C(O)-, etc.; X = -O- or -NR6- when the double dotted line represents a single bond, or X is -OH or -NHR20 when the bond is absent; Y = =O, =S, (H, H), (H, OH) or (H, alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y =O, (H, H), (H, OH), (H, SH) or (H, C1-C6 alkoxy); R15 is absent when the double dotted line represents a single bond and is H, -NR18R19, or -OR17 when the bond is absent; or Y = -O-(CH2)m-O- or -S-(CH2)m-S-, m = 1-2; and R15, R17, R18, R19 = H or alkyl, aryl etc.] or a pharmaceutically acceptable salt were synthesized. Thus (II) was prepared starting from (R)-3-butyn-2-ol and via condensation of fragment (III) and [5-[3-(trifluoromethyl)phenyl]-2-pyridinyl]methyl-phosphonic acid di-Et ester. II shows an IC50 of 0.11 nM in in vitro thrombin receptor antagonist assay. Phamaceutical compns. containing I as well as method of treating diseases associated with thrombosis, atherosclerosis, restenosis, **hypertension**, angina pectoris, arrhythmia, heart failure, and cancer are described.

IT **226913-30-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of himbacine analog as thrombin receptor antagonists)

RN 226913-30-0 HCAPLUS
CN Urea, N-[3-[6-[(1E)-2-[(3R,3aS,4S,4aR,8aS,9aR)-dodecahydro-3-methyl-1-oxonaphtho[2,3-c]furan-4-yl]ethenyl]-3-pyridinyl]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:640160 HCAPLUS
DOCUMENT NUMBER: 131:271803
TITLE: Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming Fai; Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Kois, Adam; Verner, Erik Joel; Castillo, Rosario Silvestre; Yalamorri, Venkatachalapathi; Balaji, Vitukudi Narayanaiyengar
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 477,223. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962490	A	19991005	US 1996-721183	19960927 <--
US 5464853	A	19951107	US 1993-142159	19931021 <--
US 5514691	A	19960507	US 1993-142552	19931021 <--
US 5591761	A	19970107	US 1994-222287	19940405 <--
US 5571821	A	19961105	US 1994-247072	19940520 <--
US 5594021	A	19970114	US 1995-477223	19950606 <--
WO 9631492	A1	19961010	WO 1996-US4759	19960404 <--

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

CA 2261760	AA	19980402	CA 1997-2261760	19970926	<--
CA 2261760	C	20050329			
WO 9813366	A1	19980402	WO 1997-US17402	19970926	<--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9745059	A1	19980417	AU 1997-45059	19970926	<--
AU 736269	B2	20010726			
EP 946552	A1	19991006	EP 1997-943629	19970926	<--
EP 946552	B1	20040707			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

CN 1231664	A	19991013	CN 1997-198343	19970926	<--
BR 9711550	A	20000118	BR 1997-11550	19970926	<--
JP 2000507607	T2	20000620	JP 1998-515979	19970926	<--
NZ 334797	A	20010223	NZ 1997-334797	19970926	<--
US 6420567	B1	20020716	US 1997-938325	19970926	<--
JP 2002308875	A2	20021023	JP 2002-101613	19970926	<--
EP 1342721	A1	20030910	EP 2003-7240	19970926	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL

AT 270669	E	20040715	AT 1997-943629	19970926	<--
CN 1530366	A	20040922	CN 2003-2003158478	19970926	<--
PT 946552	T	20041029	PT 1997-943629	19970926	<--
ES 2224271	T3	20050301	ES 1997-943629	19970926	<--
NO 9901388	A	19990527	NO 1999-1388	19990322	<--
US 6331637	B1	20011218	US 1999-274280	19990322	<--
KR 2000048681	A	20000725	KR 1999-702629	19990326	<--
AU 9935803	A1	19990916	AU 1999-35803	19990622	<--
AU 726595	B2	20001116			
US 2002091272	A1	20020711	US 2001-11610	20011105	<--
US 6632829	B2	20031014			
US 2003208084	A1	20031106	US 2003-447763	20030528	<--

PRIORITY APPLN. INFO.:

US 1987-100865	A2	19870925	<--
US 1990-416199	A2	19900515	<--
US 1993-65202	B2	19930520	<--
US 1993-100125	B2	19930730	<--
US 1993-100565	A2	19930730	<--
US 1993-142159	A2	19931021	<--
US 1993-142552	A2	19931021	<--
US 1993-142631	B2	19931021	<--
US 1994-222287	A2	19940405	<--
US 1994-247072	A2	19940520	<--
US 1995-417075	A2	19950404	<--
US 1995-477223	A2	19950606	<--
WO 1996-US4759	A2	19960404	<--
US 1995-416199	A	19950404	<--
AU 1996-55367	A	19960404	<--
US 1996-721183	A	19960927	<--
EP 1997-943629	A3	19970926	<--
JP 1998-515979	A3	19970926	<--
US 1997-938325	A3	19970926	<--
WO 1997-US17402	W	19970926	<--
US 2001-11610	A3	20011105	

OTHER SOURCE(S): MARPAT 131:271803
GI



II



III

AB Thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides, are provided. In particular, the disclosure includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; Ar1 = (un)substituted aryl, particularly isoxazolyl; Ar2 = biol. effective group for inhibiting endothelin binding by ≥ 50% at ≤100 μM, notably thienyl, furyl, pyrrolyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include **hypertension**, cardiovascular disease, asthma, **hypertension**, inflammatory disease, glaucoma, etc. Approx. 190 synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 5-amino-4-bromo-3-methylisoxazole was treated with NaH in THF, followed by thiophene-2-sulfonyl chloride, to give 34% title compound II. The similarly prepared title compound III had IC50 values of 0.024 μM for ETA receptors and 7.95 μM for ETB receptors, indicating substantial selectivity for ETA.

IT **184035-57-2P**, N-(4-Bromo-3-methyl-5-isoxazolyl)-2-[N'-[3,4-(methylenedioxy)phenyl]ureido]thiophene-3-sulfonamide **184035-67-4P**, N,N'-Bis[3-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea **184035-68-5P**, N,N'-Bis[3-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]thien-2-yl]urea
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 184035-57-2 HCAPLUS

CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-67-4 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-68-5 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:584815 HCAPLUS
DOCUMENT NUMBER: 131:214296
TITLE: Preparation of 2-amino-4-naphthylpyrimidines and related compounds as 5HT2B antagonists.
INVENTOR(S): Berger, Jacob; Flippin, Lee Allen; Greenhouse, Robert; Jaime-Figueroa, Saul; Liu, Yanzhou; Miller, Aubry Kern; Putman, David George; Weinhardt, Klaus Kurt; Zhao, Shu-Hai
PATENT ASSIGNEE(S): Syntex (USA) Inc., USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,863,924.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 5952331	A	19990914	US 1997-963390		19971103	<--
CN 1223641	A	19990721	CN 1997-196018		19970514	<--
CN 1109675	B	20030528				
ZA 9704281	A	19971124	ZA 1997-4281		19970516	<--
US 5863924	A	19990126	US 1997-858964		19970520	
US 5958934	A	19990928	US 1997-976418		19971121	<--
PRIORITY APPLN. INFO.:			US 1996-18218P	P	19960523	<--
			US 1997-40377P	P	19970310	<--
			US 1997-858964	A2	19970520	<--
			US 1997-963390	A2	19971103	<--

OTHER SOURCE(S): MARPAT 131:214296
GI



I

AB Title compds. [I; R1 = H, alkyl, alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl,alkyl, thioalkoxy, halo, fluoroalkyl, amino, CO2H, alkoxycarbonyl, etc.; R2 = H, alkyl, alkoxy, halo, fluoroalkyl; R3 = (substituted) aryl; R4 = H, alkyl, cycloalkyl, alkenyl, acyl, amino, amido, aryl, (substituted) alkyl; R5 = H, alkyl], were prepared for treatment of gastrointestinal disorders, restenosis, asthma, obstructive airway disease, prostatic hyperplasia, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, alcoholism, depression, **hypertension**, sleep disorders, anorexia nervosa, and priapism (no data). Thus, 1-naphthylboronic acid, 2-amino-4-chloro-5,6-dimethylpyrimidine, EtOH, H2O, 1,2-dimethoxyethane, Na2CO3, and Pd(PPh3)4 were refluxed 14 h to give 2-amino-5,6-dimethyl-4-(1-naphthyl)pyrimidine. I drug formulations are given.

IT **199866-45-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-amino-4-naphthylpyrimidines and related compds. as 5HT2B antagonists)

RN 199866-45-0 HCAPLUS

CN Urea, N-[4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:439309 HCAPLUS
DOCUMENT NUMBER: 131:82984
TITLE: Endothelin antagonists, pharmaceutical compositions, and therapeutic use
INVENTOR(S): Doherty, Annette Marian; Rees, David Charles
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 12 pp.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5922681	A	19990713	US 1992-945316	19920914 <--
PRIORITY APPLN. INFO.:			US 1992-945316	19920914 <--

OTHER SOURCE(S): MARPAT 131:82984

AB Antagonists of endothelin are described, as well as methods of using them and pharmaceutical compns. containing them. These compds. are useful in controlling **hypertension**, myocardial infarction, pulmonary **hypertension**, angina, metabolic, endocrinol., and neurol. disorders, congestive heart failure, septic or endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, preeclampsia, and diabetes.

IT **229618-71-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonists, pharmaceutical compns., and therapeutic use)

RN 229618-71-7 HCAPLUS
CN D-Tryptophan, N-[(cyclohexylamino)carbonyl]-α-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:355771 HCAPLUS
DOCUMENT NUMBER: 131:32085
TITLE: Preparation of himbacine analogs for use as thrombin receptor antagonists
INVENTOR(S): Chackalamannil, Samuel; Asberom, Theodros; Xia, Yan; Doller, Dario; Clasby, Martin C.; Czarniecki, Michael F.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9926943	A1	19990603	WO 1998-US24523	19981123 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309352	AA	19990603	CA 1998-2309352	19981123 <--
CA 2309352	C	20050125		
AU 9914158	A1	19990615	AU 1999-14158	19981123 <--
AU 747204	B2	20020509		
ZA 9810685	A	19991223	ZA 1998-10685	19981123 <--
EP 1036072	A1	20000920	EP 1998-958039	19981123 <--
EP 1036072	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
TR 200001480	T2	20000921	TR 2000-200001480	19981123 <--
BR 9812793	A	20001017	BR 1998-12793	19981123 <--
JP 2001524479	T2	20011204	JP 2000-522101	19981123 <--
JP 3449620	B2	20030922		
JP 2003128670	A2	20030508	JP 2002-315015	19981123 <--
RU 2204557	C2	20030520	RU 2000-116548	19981123 <--
IL 135797	A1	20030917	IL 1998-135797	19981123 <--
AT 266025	E	20040515	AT 1998-958039	19981123 <--
PT 1036072	T	20040831	PT 1998-958039	19981123 <--
ES 2219919	T3	20041201	ES 1998-958039	19981123 <--
NO 2000002659	A	20000724	NO 2000-2659	20000524 <--
HK 1031726	A1	20040930	HK 2001-101899	20010316 <--
PRIORITY APPLN. INFO.:			US 1997-977979 A	19971125 <--
			JP 2000-522101 A3	19981123
			WO 1998-US24523 W	19981123

OTHER SOURCE(S): MARPAT 131:32085

GI



I



III



II

AB Himbacine analogs I [R = heteroaryl, such as pyridinyl, quinolinyl, isoquinolinyl, etc; R1, R2, R8, R10, R11 = H, alkyl, fluoroalkyl, cycloalkyl, alkenyl, aryl, heteroaryl, etc.; R3 = H, OH, alkoxy,

alkylsulfinyl, alkylsulfonyl, alkyl, carboxyl, carbamido, aryl, etc.; R4, R5 = H, OH, alkyloxy, alkyl, amino, etc.; R4R5 = O, S; R6 = H; R6R10 = bond; R7R12 = fused alicyclic, fused aryl, fused heteroaryl, etc.; R9 = H, OH, alkoxy, halogen, haloalkyl; X = O, NR13; R13 = H, alkyl, Ph, etc.; Y = (CH2)n, n = 0 - 2; Z = connecting group, such as CH:CH, CH2CH2, CH2O, CH2S, CH2NH, CONH, etc.] were prepared for use as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, atherosclerosis, restenosis, **hypertension**, angina pectoris, arrhythmia, heart failure, and cancer. Thus, lactone II was prepared starting from (R)-3-butyn-2-ol, trans-3-(1-cyclohexenyl)acrylic acid, and 6-hydroxyquinaldine via the formation and intramol. cycloaddn. of diester III. The prepared compds. were tested for thrombin receptor binding, platelet aggregation and antitumor activity.

IT **226913-30-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of himbacine analogs for use as thrombin receptor antagonists)

RN 226913-30-0 HCAPLUS

CN Urea, N-[3-[6-[(1E)-2-[(3R,3aS,4S,4aR,8aS,9aR)-dodecahydro-3-methyl-1-oxonaphtho[2,3-c]furan-4-yl]ethenyl]-3-pyridinyl]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:788746 HCAPLUS
DOCUMENT NUMBER: 130:52406
TITLE: Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
INVENTOR(S): Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 107 pp., Cont.-in-part of U.S. Ser. No. 754,715, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5846990	A	19981208	US 1997-799616	19970213 <--
TW 517057	B	20030111	TW 1997-86101898	19970218 <--
ZA 9701423	A	19980819	ZA 1997-1423	19970219 <--
CA 2240043	AA	19970821	CA 1997-2240043	19970220 <--
WO 9729748	A1	19970821	WO 1997-US3956	19970220 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9722098	A1	19970902	AU 1997-22098	19970220 <--
AU 720458	B2	20000601		
EP 921800	A1	19990616	EP 1997-915055	19970220 <--
EP 921800	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002500619	T2	20020108	JP 1997-529620	19970220 <--
AT 264324	E	20040415	AT 1997-915055	19970220 <--
ES 2219762	T3	20041201	ES 1997-915055	19970220 <--

PRIORITY APPLN. INFO.:		
US 1995-493331	B2	19950724 <--
US 1996-603975	B1	19960220 <--
US 1996-754715	B2	19961121 <--
US 1997-799616	A	19970213 <--
WO 1997-US3956	W	19970220 <--

OTHER SOURCE(S): MARPAT 130:52406
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.

IT **176960-71-7P 176960-74-0P 176960-75-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)

RN 176960-71-7 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(methylamino)carbonyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 176960-74-0 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[[[(phenylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 176960-75-1 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-

oxazolyl)-2'-[[[(propylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:635749 HCAPLUS
DOCUMENT NUMBER: 129:260474
TITLE: Preparation of novel benzolactam derivatives as neuropeptide antagonists and medicinal compositions comprising them
INVENTOR(S): Hagishita, Sanji; Okada, Tetsuo; Fujimoto, Masafumi
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841510	A1	19980924	WO 1997-JP814	19970314 <--
W: JP				
PRIORITY APPLN. INFO.:			WO 1997-JP814	19970314 <--

OTHER SOURCE(S): MARPAT 129:260474
GI



I



II



AB Claimed are compds. represented by general formula (I; R1, R2 = H, halo, OH, NO2, (un)substituted lower alkyl, alkoxy, alkoxycarbonyl, or alkoxycarbonylamino, CO2H; R3 = (un)substituted lower alkyl, aryl-lower alkyl, or heterocyclyl-lower alkyl; R4 = acylamino, (un)substituted (thio)ureido, guanidino, lower alkyl, or acyl; X = CH2, S, O; n = 1,2; provisos given), pharmaceutically acceptable salts thereof, or hydrates of these; pharmaceutical compns. comprising the same; a method for inhibiting feeding characterized by administering the same; a method for treating myocardial infarction, angina pectoris and **hypertension**; and the use of the same in the inhibition of feeding, the preparation of medicines for treating myocardial infarction, angina pectoris and **hypertension** . Thus, 3-(N-phenylureido)-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one was alkylated by 3-(tert-butoxycarbonylamino)benzyl bromide gave the title compound (II; X = S, R = Boc, R4 = NHCONHPh). The latter compound and II (X = CH2, R = CONHCHMe2, R4 = Q) inhibited the binding of 125I-peptide YY to neuropeptide YY1 receptor in SK-N-MC cells with IC50 of 1.5 and 0.0032 μM, resp.

IT **211759-80-7P 211759-81-8P 211759-83-0P**
211759-84-1P 211759-85-2P 211759-86-3P
211759-87-4P 211759-88-5P 211759-89-6P
211759-91-0P 211759-92-1P 211759-93-2P
211759-94-3P 211759-95-4P 211759-96-5P
211759-97-6P 211759-98-7P 211759-99-8P
211760-00-8P 211760-01-9P 211760-02-0P
211760-03-1P 211760-04-2P 211760-05-3P
211760-07-5P 211760-08-6P 211760-09-7P
211760-11-1P 211760-12-2P 211760-13-3P
211760-14-4P 211760-15-5P 211760-16-6P
211760-17-7P 211760-18-8P 211760-19-9P
211760-20-2P 211760-21-3P 211760-22-4P
211760-23-5P 211760-24-6P 211760-25-7P
211760-27-9P 211760-28-0P 211760-29-1P
211760-30-4P 211760-32-6P 211760-33-7P
211760-34-8P 211760-37-1P 211760-39-3P
211760-40-6P 211760-56-4P 211760-57-5P
211760-58-6P 211760-59-7P 211760-61-1P
211760-64-4P 211760-65-5P 211760-66-6P
211760-68-8P 211760-70-2P 211760-71-3P
211760-72-4P 211760-73-5P 211760-74-6P

211760-75-7P 211760-76-8P 211760-77-9P
211760-79-1P 211760-80-4P 211760-81-5P
211760-82-6P 211760-83-7P 211760-84-8P
211760-85-9P 211760-86-0P 211760-87-1P
211760-88-2P 211760-89-3P 211760-90-6P
211760-91-7P 211760-92-8P 211760-93-9P
211760-94-0P 211760-95-1P 211760-96-2P
211760-97-3P 211760-98-4P 211760-99-5P
211761-00-1P 211761-02-3P 211761-03-4P
211761-04-5P 211761-05-6P 211761-06-7P
213664-48-3P 213664-49-4P 213664-50-7P
213664-51-8P 213664-52-9P 213664-53-0P
213664-54-1P 213664-55-2P 213664-57-4P
213664-58-5P 213664-59-6P 213664-60-9P
213664-63-2P 213664-64-3P 213664-65-4P
213664-66-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel benzolactam derivs. as neuropeptide antagonists and medicinal compns. comprising them)

RN 211759-80-7 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[(methylamino)carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211759-81-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 2,3,4,5-tetrahydro-3-[[(methylamino)carbonyl]amino]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211759-83-0 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-1-(1-naphthalenylmethyl)-2-oxo-1H-1-

benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-84-1 HCAPLUS
CN Urea, N-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 211759-85-2 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-2-oxo-1-(2-quinolinylmethyl)-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-86-3 HCAPLUS
CN Urea, N-[1-[bis(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 211759-87-4 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-88-5 HCAPLUS
CN Urea, N-[1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 211759-89-6 HCAPLUS

CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[(methylamino)carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 211759-91-0 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-92-1 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-1-[2-(3-nitrophenyl)-2-oxoethyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-93-2 HCAPLUS
CN Urea, N-[1-(diphenylmethyl)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 211759-94-3 HCAPLUS
CN Urea, N-methyl-N'-[2,3,4,5-tetrahydro-1-[(4-hydroxyphenyl)methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211759-95-4 HCAPLUS
CN Urea, N-[1-(3-aminopropyl)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 211759-96-5 HCAPLUS
CN Carbamic acid, [[3-[2,3,4,5-tetrahydro-2-oxo-3-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]propyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 211759-97-6 HCAPLUS
CN Carbamic acid, [[3-[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]propyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 211759-98-7 HCAPLUS
CN Urea, N-[1-[3-[(aminoiminomethyl)amino]propyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 211759-99-8 HCAPLUS
CN Urea, N-[1-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 211760-00-8 HCAPLUS
CN Carbamic acid, [[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 211760-01-9 HCAPLUS
CN Carbamic acid, [[3-[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 211760-02-0 HCAPLUS
CN Urea, N-[1-[[3-[(aminoiminomethyl)amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 211760-03-1 HCAPLUS
CN Urea, N-[1-[(3-cyanophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-04-2 HCAPLUS

CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-05-3 HCAPLUS
CN Carbamic acid, [2-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-07-5 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[(phenylmethyl)amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-08-6 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-09-7 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-11-1 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[4-(1H-tetrazol-5-yl)phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-12-2 HCAPLUS
CN Carbamic acid, [3-[[3-[[[[4-(3-chloropropoxy)phenyl]amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-13-3 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[3-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-14-4 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[(3-hydroxyphenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-15-5 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[(2-hydroxyphenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-16-6 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(3-pyridinylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-17-7 HCAPLUS
CN Carbamic acid, [3-[[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-18-8 HCAPLUS
CN Carbamic acid, [3-[[3-[[(6-benzothiazolylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-19-9 HCAPLUS
CN Carbamic acid, [3-[[3-[[(1H-benzotriazol-5-ylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-20-2 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[[1-[(4-methylphenyl)sulfonyl]-1H-benzimidazol-5-yl]amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-21-3 HCAPLUS
CN Carbamic acid, [3-[[3-[[(1H-benzimidazol-5-ylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-22-4 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[2-[4-(phenylmethoxy)phenyl]ethyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-23-5 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-24-6 HCAPLUS
CN Carbamic acid, [carbonylbis[imino(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-3,1-diyl)methylene-3,1-phenylene]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 211760-25-7 HCAPLUS
CN Benzoic acid, 4-[[[[1-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 211760-27-9 HCAPLUS
CN Urea, N-[1-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-28-0 HCAPLUS

CN Methanesulfonamide, N-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-29-1 HCAPLUS
CN Methanesulfonamide, N-(methylsulfonyl)-N-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-30-4 HCAPLUS
CN 2-Propanesulfonamide, N-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-32-6 HCAPLUS
CN Urea, N-phenyl-N'-[2,3,4,5-tetrahydro-1-[[3-[[1-(methylthio)-2-nitroethenyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211760-33-7 HCAPLUS
CN Urea, N-[1-[[3-[[(cyanoamino)(methylamino)methylene]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-34-8 HCAPLUS
CN Urea, N-phenyl-N'-[2,3,4,5-tetrahydro-1-[[3-[[1-(methylamino)-2-nitroethenyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211760-37-1 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-7-methoxy-3-[[(methylamino)carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-39-3 HCAPLUS
CN Carbamic acid, [3-[[3,4-dihydro-4-oxo-3-[[(phenylamino)carbonyl]amino]-1,5-benzothiazepin-5(2H)-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-40-6 HCAPLUS
CN Carbamic acid, [3-[[(3S)-3,4-dihydro-4-oxo-3-[[(phenylamino)carbonyl]amino]-1,5-benzothiazepin-5(2H)-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211760-56-4 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[3-[[(methylamino)carbonyl]amino]-1-oxopropyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-57-5 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[1-oxo-3-[[[(phenylmethyl)amino]carbonyl]amino]propyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-58-6 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[1-oxo-3-[[(propylamino)carbonyl]amino]propyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-59-7 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[1-oxo-3-[[[[2-[4-(phenylmethoxy)phenyl]ethyl]amino]carbonyl]amino]propyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-61-1 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[3-[[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]amino]-1-oxopropyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-64-4 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino](methylamino)methylene]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-65-5 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-66-6 HCAPLUS
CN Urea, N-[3-[[3-[[[(6-benzothiazolylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211760-68-8 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)thioxomethyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-70-2 HCAPLUS
CN Urea, N-[1-[[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-71-3 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-3-[[[(1-methylethyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-72-4 HCAPLUS
CN Carbamic acid, [3-[[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-73-5 HCAPLUS
CN Carbamic acid, [3-[[3,4-dihydro-4-oxo-3-[[(phenylamino)carbonyl]amino]-1,5-benzoxazepin-5(2H)-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-74-6 HCAPLUS
CN Carbamic acid, [3-[[3-[[[[4-(aminosulfonyl)phenyl]amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-75-7 HCAPLUS
CN Carbamic acid, [3-[[3-[[(cyclohexylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-76-8 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(2-pyrimidinylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-77-9 HCAPLUS
CN Carbamic acid, [3-[[3-[[(benzoylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-79-1 HCAPLUS
CN 4-Morpholinecarboxamide, N-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-80-4 HCAPLUS
CN Carbamic acid, methyl[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211760-81-5 HCAPLUS
CN Urea, N-[1-[[3-[(aminocarbonyl)amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-82-6 HCAPLUS
CN Urea, N-methyl-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-83-7 HCAPLUS
CN Urea, N-[1-[[3-[[(cyclopropylamino)carbonyl]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-84-8 HCAPLUS
CN Urea, N-[1-[[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 211760-85-9 HCAPLUS

CN Urea, N-(1-methylpropyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-86-0 HCAPLUS
CN Urea, N-phenyl-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-87-1 HCAPLUS
CN Urea, N-[3-[[3,4-dihydro-4-oxo-3-[[(phenylamino)carbonyl]amino]-1,5-benzoxazepin-5(2H)-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211760-88-2 HCAPLUS
CN Urea, N-[1,2,3,4,5,6-hexahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1-benzazocin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 211760-89-3 HCAPLUS
CN Urea, N-(4-hydroxyphenyl)-N'-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211760-90-6 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-3-[[[(4-nitrophenyl)amino]carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-91-7 HCAPLUS
CN Urea, N-[3-[[3-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211760-92-8 HCAPLUS
CN Urea, N-[3-[[3-[[[(4-fluorophenyl)amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211760-93-9 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(2-thiazolylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-94-0 HCAPLUS
CN Urea, N-(6-methoxy-3-pyridinyl)-N'-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211760-95-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[[[[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 211760-96-2 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(1,3,4-thiadiazol-2-ylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-97-3 HCAPLUS
CN Urea, N-[3-[[3-[[[(2-benzothiazolylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211760-98-4 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(4-pyridinylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211760-99-5 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(pyrazinylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211761-00-1 HCAPLUS
CN Urea, N-[3-[[3-[[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-02-3 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(1H-pyrazol-3-ylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211761-03-4 HCAPLUS
CN Urea, N-[3-[[3-[[[(1,6-dihydro-6-oxo-3-pyridinyl)amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-04-5 HCAPLUS
CN Urea, N-(2-hydroxyethyl)-N'-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211761-05-6 HCAPLUS
CN Hydrazinecarboxamide, 2-phenyl-N-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211761-06-7 HCAPLUS
CN Carbamic acid, [2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213664-48-3 HCAPLUS
CN 1H-1-Benzazepine-1-acetamide, N-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-3-[[(methylamino)carbonyl]amino]-2-oxo- (9CI) (CA INDEX NAME)



RN 213664-49-4 HCAPLUS
CN Butanamide, 3,3-dimethyl-N-[3-[[2,3,4,5-tetrahydro-3-[[(methylamino)carbonyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-50-7 HCAPLUS

CN Benzenecarboximidamide, 3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 213664-51-8 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[[4-(sulfooxy)phenyl]amino]carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, C-(1,1-dimethylethyl) ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 213664-52-9 HCAPLUS
CN Benzenecarboximidic acid, N-cyano-3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(phenylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 213664-53-0 HCAPLUS
CN Thiourea, N-[1-[[3-[[(cyanoamino)[(1-ethylpropyl)amino]methylene]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 213664-54-1 HCAPLUS
CN Thiourea, N-[1-[[3-[[1-[(1-ethylpropyl)amino]-2-nitroethenyl]amino]phenyl]methyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 213664-55-2 HCAPLUS
CN Carbamic acid, [3-[[2,3,4,5-tetrahydro-2-oxo-3-[[[(phenylmethyl)amino]thioxomethyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 213664-57-4 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-3-[[(methylamino)(phenylamino)methylene]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-58-5 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-2-oxo-3-[[(6-quinolinylamino)carbonyl]amino]-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-59-6 HCAPLUS
CN Carbamoperoxoic acid, [2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 213664-60-9 HCAPLUS
CN Urea, N-phenyl-N'-[3-[[[2,3,4,5-tetrahydro-3-[[imino(phenylamino)methyl]amino]-2-oxo-1H-1-benzazepin-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-63-2 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino][(1-methylethyl)amino]methylene]amino]-2-oxo-1H-1-benzazepin-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-64-3 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino]iminomethyl]amino]-2-oxo-1H-1-benzazepin-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-65-4 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[[2,3,4,5-tetrahydro-3-[[[(2-hydroxyethyl)amino][(4-hydroxyphenyl)amino]methylene]amino]-2-oxo-1H-1-benzazepin-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-66-5 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[[2,3,4,5-tetrahydro-3-[[(methylamino)(phenylamino)methylene]amino]-2-oxo-1H-1-benzazepin-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



IT **211761-48-7P 211761-50-1P 211761-56-7P**
211761-57-8P 211761-58-9P 211761-64-7P
211761-67-0P 211761-68-1P 211761-69-2P
211761-71-6P 211761-72-7P 211761-73-8P
211761-74-9P 211761-76-1P 213664-67-6P
213664-71-2P 213664-72-3P 213664-73-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel benzolactam derivs. as neuropeptide antagonists and medicinal compns. comprising them)

RN 211761-48-7 HCAPLUS
CN Urea, N-methyl-N'-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 211761-50-1 HCAPLUS
CN Carbamic acid, [3-[[3-[[[[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 211761-56-7 HCAPLUS
CN Carbamimidothioic acid, N-phenyl-N'-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 211761-57-8 HCAPLUS
CN Urea, N-[3-[(3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)methyl]phenyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 211761-58-9 HCAPLUS
CN Urea, N-[4-(phenylmethoxy)phenyl]-N'-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 211761-64-7 HCAPLUS
CN Urea, N-phenyl-N'-(2,3,4,5-tetrahydro-4-oxo-1,5-benzothiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 211761-67-0 HCAPLUS
CN Urea, N-[3-[(3-azido-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-68-1 HCAPLUS
CN Urea, N-[3-[(3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)methyl]phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-69-2 HCAPLUS
CN 1H-Imidazole-1-carboxamide, N-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 211761-71-6 HCAPLUS
CN Carbamimidothioic acid, N-(4-hydroxyphenyl)-N'-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 211761-72-7 HCAPLUS
CN Urea, N-[3-(hydroxymethyl)phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-73-8 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[(methylsulfonyl)oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211761-74-9 HCAPLUS
CN Urea, N-[3-(bromomethyl)phenyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 211761-76-1 HCAPLUS
CN Urea, N-[3-[(3-azido-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)methyl]phenyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 213664-67-6 HCAPLUS
CN Urea, N-[1-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 213664-71-2 HCAPLUS
CN 1H-Imidazole-1-carbothioamide, N-[2,3,4,5-tetrahydro-1-[[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]methyl]-2-oxo-1H-1-benzazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 213664-72-3 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-3-[[[[4-(methoxymethoxy)phenyl]amino]thioxomethyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213664-73-4 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[[2,3,4,5-tetrahydro-3-[[[(4-hydroxyphenyl)amino]thioxomethyl]amino]-2-oxo-1H-1-benzazepin-1-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:199752 HCAPLUS
DOCUMENT NUMBER: 128:213071
TITLE: Antihypertensive effects of different talinolol dosages after 4 weeks of treatment in comparison with placebo
AUTHOR(S): Weigmann, Ingo; Terhaag, Bernd; Wierich, Werner; Herrmann, Werner M.
CORPORATE SOURCE: Abt. Medizinische Forschung, Arzneimittelwerk Dresden G.m.b.H., Radebeul, D-01445, Germany
SOURCE: Arzneimittel-Forschung (**1998**), 48(3), 240-244
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Editio Cantor Verlag
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The dose dependence of the antihypertensive effect of the β1 selective blocker talinolol (CAS **57460-41-0**, Cordanum) was investigated in 97 essential hypertensive patients (mild to moderate) using the ambulatory blood pressure monitoring (ABPM) in a single-center, double-blind, randomized parallel-group study. After 4 wk of treatment a comparison was made between the once daily administered doses of 50, 100, and 200 mg as well as with placebo. The primary parameter was the mean diastolic blood pressure between 8.00 and 22.00 (dTMW). Furthermore, the duration of action of the once daily administration of 200 mg talinolol was compared with the twice daily application of 100 mg each. With regard to dTMW an increasing antihypertensive effect was determined for the dosage step from 50 mg to 100 mg talinolol/d. No further increase in the blood pressure lowering effect was observed with 200 mg talinolol/d. The highest frequency of therapy responders was found in the 100 mg group with 72,2%. Moreover it could be demonstrated, that within the dosage range of 1 + 100-200 mg talinolol/d a 24 h lasting reduction of blood pressure and pulse rate was achieved, including the early morning period. There were no differences between the blood pressure profile of the 200 mg group and the 2 + 100 mg group at the end of the 4 wk treatment. All talinolol dosages investigated in this study were proved to be safe and well tolerated. The observed complaints classified as adverse drug reactions represented typical side effects of β-blockers of mild to moderate intensity. It can be concluded from the results that the once daily intake of talinolol in the dosage range of 100-200 mg/d shows a reliable efficacy in the treatment of essential **hypertension** accompanied by a noncrit. safety profile.

IT **57460-41-0**, Talinolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cordanum; antihypertensive effects of different talinolol dosages)

RN 57460-41-0 HCAPLUS
CN Urea, N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 16 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:87719 HCAPLUS
DOCUMENT NUMBER: 128:154097
TITLE: Preparation of certain substituted benzylamine derivatives such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands
INVENTOR(S): Blum, Charles A.; Hutchison, Alan; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corp., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9803492	A1	19980129	WO 1997-US12614		19970718	<--
W: CA, JP, MX						
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
CA 2261031	AA	19980129	CA 1997-2261031		19970718	<--
EP 915859	A1	19990519	EP 1997-934217		19970718	<--
EP 915859	B1	20030102				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI						
US 5962455	A	19991005	US 1997-897045		19970718	<--
JP 2000515150	T2	20001114	JP 1998-507101		19970718	<--
AT 230403	E	20030115	AT 1997-934217		19970718	<--
ES 2186907	T3	20030516	ES 1997-934217		19970718	<--
MX 9900870	A	20000331	MX 1999-870		19990122	<--
PRIORITY APPLN. INFO.:			US 1996-22296P	P	19960723	<--
			WO 1997-US12614	W	19970718	<--

OTHER SOURCE(S): MARPAT 128:154097
GI



I



II

AB The title compds. [I; one of X1, X2 and X3 = -N(Ro)C(O)N(Rp)Y and the remaining X1, X2 and X3 = H; Y = (un)substituted Ph, pyridyl, naphthyl, etc.; Ro, Rp = H, C1-6 alkyl, etc.; RoRp = (CH2)n; n = 1-3; Ar = (un)substituted Ph, pyridyl, thienyl, pyrimidyl; B = S, O, N(R5), C(R5)(R6); n = 1-3; m = 2-4; R1, R2 = H, C1-6 alkyl; R3, R4 = H, C1-6 alkyl, C1-6 alkoxy; R5 = C1-6 alkyl, Ph, pyridyl; R6 = H, OH, NH2, etc.], useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential **hypertension** and congestive heart failure due to the binding of these compds. to mammalian neuropeptide Y1 receptors, were prepared Thus, treatment of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane (preparation described) with phosgene in the presence of Et3N in CH2Cl2 followed by addition of 3-aminoquinoline afforded the title compound cis-II. Compds. I are effective at 0.1-140 mg/kg/day.

IT **202472-67-1P 202472-68-2P 202472-69-3P**
202472-70-6P 202472-71-7P 202472-72-8P
202472-73-9P 202472-74-0P 202472-75-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of certain substituted benzylamine derivs. such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands)

RN 202472-67-1 HCAPLUS

CN Urea, N-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-3-quinolinyl-, trihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 202472-68-2 HCAPLUS
CN Urea, N-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-6-quinolinyl-, trihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 202472-69-3 HCAPLUS
CN Urea, N-(3-fluorophenyl)-N'-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl



RN 202472-70-6 HCAPLUS
CN Urea, N-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-2-pyridinyl-, trihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl



RN 202472-71-7 HCAPLUS
CN Urea, N-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-3-pyridinyl-, trihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl



RN 202472-72-8 HCAPLUS
CN Urea, N-[3-[4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-2-naphthalenyl-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 202472-73-9 HCAPLUS
CN Urea, N-[3-[3-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-N'-3-quinolinyl-, trihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 202472-74-0 HCAPLUS
CN Urea, N-[3-[1-[4-(4-fluorophenyl)-1-piperazinyl]-4-methylcyclohexyl]phenyl]-N'-3-quinolinyl-, trihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

●3 HCl

RN 202472-75-1 HCAPLUS
CN Urea, N-(4-fluorophenyl)-N'-[3-[4-methyl-1-(4-phenyl-1-

piperazinyl)cyclohexyl]phenyl]-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 17 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:81044 HCAPLUS
DOCUMENT NUMBER: 128:192655
TITLE: Preparation of 4-phenylpyridine derivatives as endothelin antagonists
INVENTOR(S): Sakurai, Kuniya; Niwa, Seiji; Oono, Seiji; Uchita, Hirohisa
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
JP 10029979	A2	19980203	JP 1997-93782		19970411	<--
PRIORITY APPLN. INFO.:			JP 1996-91272	A	19960412	<--

OTHER SOURCE(S): MARPAT 128:192655
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I; R1 - R11 = H, halo, OH, NH2, NO2, lower alkyl, alkoxy, alkenyl, alkylamino, alkylthio, alkanoyl, hydroxyalkyl, hydroxyalkoxy, hydroxyalkenyl, haloalkyl, haloalkoxy, or haloalkenyl, aryl-lower alkoxy, aroyl; or two of R1 - R5 groups or two of R7 - R11

groups are linked to each other to form a ring; R6 = an acidic functional group; R12 = aryl, heteroaryl, heterocyclylcarbonyl, or groups listed for R1 - R5 and R7 - R11; X = CR13R14, NR15, O, S; Y = NR16, O, S, CR17:CR18; R13 - R18 = H, lower alkyl; Z = H, OH, CO2H, lower alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, NH2, alkylamino, arylamino, heteroarylamino, acylamino, O2CNR19R20, NR21CONR22R23, O-CO2R24, NR25CO2R26, OR27, O2CR28; R19 - R28 = H, lower alkyl, aryl, heteroaryl; or R19 and R20, R21 and R22, R21 and R23, R22 and R23, or R25 and R26 are bonded to each other to form a ring; m = 0,1; n = 0-3) are prepared They are useful for the treatment of **hypertension**, Raynaud's disease, acute kidney failure, myocardial infarction, angina pectoris, cerebral infarction, atrophy of brain blood vessels, arteriosclerosis, bronchial asthma, stomach ulcer, acute liver failure, diabetes, endotoxin shock, multi-organ failure, disseminated intravascular agglutination, and/or cyclosporin-induced kidney disorders. Thus, 3-cyano-5-(3-hydroxy-1-propenyl)-4-(4-methoxyphenyl)-6-methyl-2-(3,4-methylenedioxyphenyl)pyridine was dissolved in toluene, treated with Bu3SnN3, and refluxed overnight to give 60.5% the title 4-phenyl-3-tetrazolylpyridine compound (II). II in vitro inhibited the binding of [125I]endotoxin to a pig ventricular muscle membrane preparation with a -pIC50 value of 8.1.

IT **203802-04-4P 203802-05-5P 203802-09-9P 203802-24-8P 203802-37-3P 203802-38-4P 203802-39-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpyridine derivs. as endothelin antagonists for treatment endothelin-related diseases)

RN 203802-04-4 HCAPLUS

CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 203802-05-5 HCAPLUS

CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 203802-09-9 HCAPLUS
CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 203802-24-8 HCAPLUS
CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 203802-37-3 HCAPLUS
CN Thiourea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 203802-38-4 HCAPLUS
CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 203802-39-5 HCAPLUS
CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-4-(4-methoxyphenyl)-2-methyl-5-(1H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]-N'-pyrazinyl- (9CI) (CA INDEX NAME)



IT **203804-94-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylpyridine derivs. as endothelin antagonists for treatment endothelin-related diseases)
RN 203804-94-8 HCAPLUS
CN Urea, N-[3-[6-(1,3-benzodioxol-5-yloxy)-5-cyano-4-(4-methoxyphenyl)-2-methyl-3-pyridinyl]-2-propenyl]-N'-3-pyridinyl- (9CI) (CA INDEX NAME)



L18 ANSWER 18 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:557640 HCAPLUS
DOCUMENT NUMBER: 127:248103
TITLE: Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
INVENTOR(S): Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 325 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729748	A1	19970821	WO 1997-US3956	19970220 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5846990	A	19981208	US 1997-799616	19970213 <--
TW 517057	B	20030111	TW 1997-86101898	19970218 <--
ZA 9701423	A	19980819	ZA 1997-1423	19970219 <--
AU 9722098	A1	19970902	AU 1997-22098	19970220 <--
AU 720458	B2	20000601		
EP 921800	A1	19990616	EP 1997-915055	19970220 <--
EP 921800	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002500619	T2	20020108	JP 1997-529620	19970220 <--
AT 264324	E	20040415	AT 1997-915055	19970220 <--

PRIORITY APPLN. INFO.:

US 1996-603975	A	19960220 <--
US 1996-754715	A	19961121 <--
US 1997-799616	A	19970213 <--
US 1995-493331	B2	19950724 <--
WO 1997-US3956	W	19970220 <--

OTHER SOURCE(S): MARPAT 127:248103
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)3, and hydrolyzed to give 82% II [R = B(OH)2]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh3)4 catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.

IT **176960-71-7P 176960-74-0P 176960-75-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)

RN 176960-71-7 HCAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2'-[[[(methylamino)carbonyl]amino]methyl]-4'-(2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 176960-74-0 HCAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[[[(phenylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 176960-75-1 HCAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-2'-[[[(propylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 19 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:533640 HCAPLUS
DOCUMENT NUMBER: 127:220659
TITLE: Quinoline and benzimidazole derivatives as bradykinin agonists
INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Abe, Yoshito; Sawada, Yuki; Mizutani, Tsuyoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9728153	A1	19970807	WO 1997-JP233	19970131 <--
W: AU, CA, CN, JP, KR, MX, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9715569	A1	19970822	AU 1997-15569	19970131 <--
EP 879233	A1	19981125	EP 1997-901799	19970131 <--
EP 879233	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001513749	T2	20010904	JP 1997-527493	19970131 <--
AT 247103	E	20030815	AT 1997-901799	19970131 <--
ES 2202573	T3	20040401	ES 1997-901799	19970131 <--
US 6015818	A	20000118	US 1998-117453	19980803 <--
US 6127389	A	20001003	US 1999-422075	19991021 <--
PRIORITY APPLN. INFO.:			GB 1996-2029 A	19960201 <--
			WO 1997-JP233 W	19970131 <--

OTHER SOURCE(S): MARPAT 127:220659
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I [Q = ring fusions Q1 or Q2; R1 = H, alkyl, halo; R2 = alkyl, halo; R3 = amino substituted with alkyl, acyl, or -ZA2R11; R4 = heterocycloalkyl; R5 = alkyl; R6 = acylalkyl, aralkyl, heterocycloalkyl; R7 = alkyl, alkoxy; R11 = amino, acylamino; A1 = alkylene; A2 = alkylene, bond; Z = alkenylene, 1,2-pyrrolediyl, C6H4, or 2,3-thiophenediyl, latter 3 with optional halo substitution] and their pharmaceutically acceptable salts. Also disclosed are processes for preparation of the compds., pharmaceutical compns. comprising them, and methods of therapeutic use in the prevention and/or treatment of **hypertension** and the like. For instance, etherification of 2-(hydroxymethyl)pyridine with 4-chloro-8-hydroxy-2-methylquinoline gave 8-hydroxy-2-methyl-4-(2-pyridylmethoxy)quinoline, which was further etherified with 2,6-dichloro-3-[N-[[4-(methylcarbamoyl)cinnamoyl]glycyl]-N-methylamino]benzyl bromide to give title compound II. In an assay for inhibition of [3H]-bradykinin binding to guinea pig ileum receptors in vitro, II had an IC50 of 9.9 + 10-10 M.

IT **194928-54-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline and benzimidazole derivs. as bradykinin agonists)

RN 194928-54-6 HCAPLUS

CN Benzamide, 3-[[[[2-[[2,4-dichloro-3-[[[2-methyl-4-(2-pyridinylmethoxy)-8-quinolinyl]oxy]methyl]phenyl]methylamino]-2-oxoethyl]amino]carbonyl]amino]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



L18 ANSWER 20 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:473704 HCAPLUS
DOCUMENT NUMBER: 127:95085
TITLE: Preparation of aryl sulfonamide and sulfamide derivatives which bind selectively to the human Y5 receptor
INVENTOR(S): Islam, Imadul; Dhanoa, Daljit S.; Finn, John M.; Du, Ping; Gluchowski, Charles; Jeon, Yoon T.
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corporation, USA; Islam, Imadul; Dhanoa, Daljit S.; Finn, John M.; Du, Ping; Gluchowski, Charles; Jeon, Yoon T.
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719682	A1	19970605	WO 1996-US19085	19961127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9713281	A1	19970619	AU 1997-13281	19961127 <--
US 6211241	B1	20010403	US 1998-88450	19980601 <--
US 6391877	B1	20020521	US 2000-709036	20001108 <--
US 2003013714	A1	20030116	US 2002-114597	20020402 <--

US 6734182 B2 20040511
PRIORITY APPLN. INFO.: US 1995-566104 A2 19951201 <--
WO 1996-US19085 W 19961127 <--
US 1998-88450 A1 19980601
US 2000-709036 A1 20001108
OTHER SOURCE(S): MARPAT 127:95085
GI



I

AB The title compds. ArXSO2L'KW [Ar = (un)substituted Ph (generic structure given), etc.; X = NH, etc.; L' = NR1L, etc.; L = alkyl, etc.; R1 = H, alkyl; K = CH2NR10CO(CH2)3, etc.; R10 = H, alkyl; W = (un)substituted Ph (generic structure given), etc.] are prepared This invention is also related to uses of these compds. for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, **hypertension**, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 receptor may be useful. In an in vitro test for the binding affinity for the human Y5 receptor, the title compound I in vitro showed the Ki value of 14 nM.

IT **191931-97-2P 191931-98-3P 191931-99-4P**
191932-02-2P 191932-03-3P 191932-04-4P
191932-05-5P 191932-06-6P 191932-07-7P
191932-08-8P 191932-09-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl sulfonamide and sulfamide derivs. which bind selectively to the human Y5 receptor)

RN 191931-97-2 HCAPLUS
CN 1-Naphthalenesulfonamide, N-[6-[[(1-naphthalenylamino)carbonyl]amino]hexyl]- (9CI) (CA INDEX NAME)



RN 191931-98-3 HCAPLUS
CN 2-Naphthalenesulfonamide, N-[6-[[[(2-nitrophenyl)amino]carbonyl]amino]hexyl]- (9CI) (CA INDEX NAME)



RN 191931-99-4 HCAPLUS
CN Benzenesulfonamide, 2-(hydroxymethyl)-N-[6-[[(1-naphthalenylamino)carbonyl]amino]hexyl]- (9CI) (CA INDEX NAME)



RN 191932-02-2 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1-naphthalenylmethyl)amino]thioxomethyl]-1-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 191932-03-3 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1-naphthalenylmethyl)amino]carbonyl]-1-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 191932-04-4 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1,3-benzodioxol-5-ylmethyl)amino]thioxomethyl]-1-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 191932-05-5 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1,3-benzodioxol-5-ylmethyl)amino]thioxomethyl]-1-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 191932-06-6 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1-naphthalenylmethyl)amino]carbonyl]-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 191932-07-7 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1-naphthalenylmethyl)amino]thioxomethyl]-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 191932-08-8 HCAPLUS
CN 3-Pyrrolidinemethanamine, N-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 191932-09-9 HCAPLUS
CN 4-Piperidinemethanamine, N-[[(1-naphthalenylmethyl)amino]carbonyl]-1-[(2-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **191932-31-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl sulfonamide and sulfamide derivs. which bind selectively to the human Y5 receptor)
RN 191932-31-7 HCAPLUS
CN 3-Pyrrolidinemethanamine, N-[[(1-naphthalenylmethyl)amino]carbonyl]-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **191932-20-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl sulfonamide and sulfamide derivs. which bind selectively to the human Y5 receptor)
RN 191932-20-4 HCAPLUS
CN Thiourea, N-(1-naphthalenylmethyl)-N'-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 21 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:436013 HCAPLUS
DOCUMENT NUMBER: 127:95514
TITLE: Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity
AUTHOR(S): Ahn, Ho-Sam; Bercovici, Ana; Boykow, George; Bronnenkant, Alan; Chackalamannil, Samuel; Chow, Jason; Cleven, Renee; Cook, John; Czarniecki, Michael; Domalski, Carol; Fawzi, Ahmad; Green, Michael; Guendes, Asli; Ho, Ginny; Laudicina, Malvina; Lindo, Neil; Ma, Ke; Manna, Mahua; McKittrick, Brian; Mirzai, Bita; Nechuta, Terry; Neustadt, Bernard; Puchalski, Chester; Pula, Kathryn; Silverman, Lisa; Smith, Elizabeth; Stamford, Andrew; Tedesco, Richard P.; Tsai, Hsingan; Tulshian, Deen; Vaccaro, Henry; Watkins, Robert W.; Weng, Xiaoyu; Witkowski, Joseph T.; Xia, Yan; Zhang, Hongtao
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033, USA
SOURCE: Journal of Medicinal Chemistry (**1997**), 40(14), 2196-2210
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



IV

AB Tetracyclic guanines I, IV have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compds. are inactive or only weakly active as inhibitors of PDE3, which is a major isoenzyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound I [R = CH2Ph; R1 = CH2C6H4Ph-4; R2 = Me (II)], with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while I [R = CH2Ph; R1 = C.tplbond.CPh; R2 = Me (III)], with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compds. e.g. IV [R3 = H; R4 = cyclopentylmethyl; R5 = Me; R6,R7 = bond (V)] and III are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compds. I (R = H; R1 = hexyl; R2 = Me; R = H: R1 = CH2Ph; R2 = Me) and V reduced blood pressure by more than 45 mm Hg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).

IT **191982-74-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetracyclic guanine inhibitors of PDE1 and PDE5 cGMP phosphodiesterases with oral antihypertensive activity)

RN 191982-74-8 HCAPLUS

CN 1H-Imidazole-4-carboxylic acid, 5-[[(ethylamino)carbonyl]amino]-1,2-bis(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 22 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:310799 HCAPLUS
DOCUMENT NUMBER: 126:293363
TITLE: Preparation of 2-phenylsulfonyl- and 2-(heterocyclylsulfonyl)quinazoline derivatives as chymase inhibitors
INVENTOR(S): Fukami, Harukazu; Ito, Akiko; Niwata, Shinjiro; Kakutani, Saki; Sumida, Motoo; Kiso, Yoshinobu
PATENT ASSIGNEE(S): Suntory Limited, Japan

SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9711941	A1	19970403	WO 1996-JP2830	19960927 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 795548	A1	19970917	EP 1996-932039	19960927 <--
EP 795548	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ES 2175127	T3	20021116	ES 1996-932039	19960927 <--
US 5814631	A	19980929	US 1997-849114	19970528 <--
PRIORITY APPLN. INFO.:			JP 1995-285437 A	19950928 <--
			JP 1996-116557 A	19960510 <--
			WO 1996-JP2830 W	19960927 <--

OTHER SOURCE(S): MARPAT 126:293363
GI



I

AB Quinazoline derivs. represented by general formula [I; group A = benzene, pyridine, pyrrole, or pyrazole ring; m = 0-2; X = OH, NO2, halo, C1-4 (halo)alkyl, or (halo)alkoxy, C7-12 aralkyloxy; X = group to form a naphthalene or quinoline ring together with the benzene ring to which X is attached; R1, R2 = H, halo, C1-4 (halo)alkyl, NO2, cyano, pyrazolyl, tetrazolyl, C1-4 alkyl, CO2H, allyloxycarbonyl, C1-4 (un)substituted alkoxy; or R1 and R2 together with the benzene ring represent a naphthalene or quinoline ring; Z = H, C1-4 (halo)alkyl, C2-5 alkenyl, (un)substituted aralkyl, aromatic heterocyclylalkyl, C1-4 alkoxycarbonylmethyl, allyloxycarbonylmethyl, (1° or 2° amino)carbonylmethyl, (un)substituted aralkyloxymethyl; proviso given] or pharmacol. acceptable salts thereof are prepared They are useful as preventives/remedies for cardiac and circulatory diseases (e.g. **hypertension** or heart failure) caused by abnormal overprodn. of angiotensin II. Thus, a quinazolinedione derivative (II; R = H) (preparation given) was condensed with 3-(diethylamino)-1,5-dihydro-2,4,3-benzodioxaphosphepine in the presence of tetrazole in DMF, followed by oxidation with m-chloroperbenzoic acid in CH2Cl2 and hydrogenolysis over 10% Pd-C in dioxane under H atmospheric to give II [R = P(O)(OH)2]. II (R = H) and II [R = P(O)(OH)2] showed IC50 of 0.060 and 0.025 μM, resp., for inhibiting human heart chymase. The title compds. I also inhibited cathepsin G and chymotrypsin. Formulation examples containing I were given.

IT **145013-05-4**, N,N'-tert-Butoxycarbonylthiourea
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-phenylsulfonyl- and N-(heterocyclylsulfonyl)quinazoline derivs. as chymase inhibitors for treating heart or circulatory diseases)

RN 145013-05-4 HCAPLUS

CN Carbamic acid, carbonothioylbis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L18 ANSWER 23 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:169157 HCAPLUS

DOCUMENT NUMBER: 126:225315

TITLE: Bicyclic heterocyclic derivatives having α1-adrenergic and 5HT1A serotonergic activities

INVENTOR(S): Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Testa, Rodolfo

PATENT ASSIGNEE(S): Recordati S.A., Chemical and Pharmaceutical Company, Switz.

SOURCE: U.S., 84 pp., Cont.-in-part of U.S. 5,474,994. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 5605896	A	19970225	US 1994-299188		19940831	<--
US 5403842	A	19950404	US 1992-888775		19920526	<--
AU 9336296	A1	19930913	AU 1993-36296		19930223	<--
RO 112111	B3	19970530	RO 1994-1404		19930223	<--
PL 175556	B1	19990129	PL 1993-304889		19930223	<--
RU 2128656	C1	19990410	RU 1994-43324		19930223	<--
SK 280143	B6	19990910	SK 1994-1007		19930223	<--
ZA 9301278	A	19931118	ZA 1993-1278		19930224	<--
LT 3038	B	19940925	LT 1993-354		19930224	<--
CN 1079738	A	19931222	CN 1993-105852		19930526	<--
CN 1040434	B	19981028				
US 5474994	A	19951212	US 1993-67861		19930526	<--
FI 9403876	A	19940823	FI 1994-3876		19940823	<--
NO 9403140	A	19940825	NO 1994-3140		19940825	<--
PRIORITY APPLN. INFO.:			IT 1992-MI408	A	19920225	<--
			US 1992-888775	A2	19920526	<--
			US 1993-67861	A2	19930526	<--
			EP 1993-301264	A	19930222	<--
			WO 1993-EP420	A	19930223	<--

OTHER SOURCE(S): MARPAT 126:225315

GI



I



2HCl

II



III

AB Bicyclic heterocyclic derivs., such as I [X = N, O, S; W = C(O), C(S), CH(OH), bond; R2 = H, optionally substituted alkyl, alkenyl, alkylnyl, carbocycle, heterocycle; R3 = alkyl, hydroxyalkyl, Ph, OH, alkoxy, alkoxyalkyl; R6 = H, halogen, NO2, NH2, AcNH, mono-, dialkylamino, CN, OH, alkoxy, alkyl; Y = CO, CO2, CONH, CH(OH), CH:CH, CH:CHCO2, CH:CHCONH, CH2NH, CH2NHCO, CH2NHSO2, CH2O, CH2S, NH, NHCO, NHCONH, NHSO2, O, S, SO2NH, CONHO, CSNH, NHCO2, COS, CONH(CH2)m, m = 1-6; Z = N, A = (un)substituted Ph, pyrimidinyl, 1,4-benzodioxan-8-yl, benzopyran-8-yl, benzofuran-7-yl, dihydrobenzopyran-8-yl; Z = CH2N; Z = CH, A = one or two Ph, 4-FC6H4CO, 2-oxo-1-benzimidazolinyl, (CH2)nOA, n = 0-2], and their pharmaceutically acceptable salts useful as α1-adrenergic and 5HT1A serotonergic agents for the treatment of **hypertension**, urethral and lower urinary tract contractions, and other disorders are described. Thus, benzopyran II was prepared by heating 1-(2-methoxyphenyl)piperazine with benzopyran III at 180° for 5 h. II had IC50 = 29 nM for α1-adrenergic receptor binding, IC50 = 9 nM for 5HT1A receptor binding, ED25 = 45 μg/kg i.v. hypotensive effect and ED25 = 1.4 μg/kg in Na-induced urethral contractility assays.

IT **152753-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic heterocyclic derivs. having α1-adrenergic and 5HT1A serotonergic activities)

RN 152753-34-9 HCAPLUS

CN Urea, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152737-05-8
CMF C30 H32 N4 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT **152737-74-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic heterocyclic derivs. having α1-adrenergic and

5HT1A serotonergic activities)
RN 152737-74-1 HCAPLUS
CN Urea, N-(2-chloroethyl)-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)- (9CI) (CA INDEX NAME)



IT **152737-05-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic heterocyclic derivs. having α1-adrenergic and 5HT1A serotonergic activities)
RN 152737-05-8 HCAPLUS
CN Urea, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L18 ANSWER 24 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:168548 HCAPLUS
DOCUMENT NUMBER: 126:152804
TITLE: Spironolactone or other epoxy-free spirolactone-type aldosterone receptor antagonist in combination with angiotensin II antagonist for treatment of circulatory and cardiovascular disorders, including congestive heart failure
INVENTOR(S): Maclaughlan, Todd E.; Schuh, Joseph R.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Maclaughlan, Todd E.; Schuh, Joseph R.
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640258	A2	19961219	WO 1996-US9342	19960605 <--
WO 9640258	A3	19970123		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
CA 2224222	AA	19961219	CA 1996-2224222	19960605 <--
AU 9661580	A1	19961230	AU 1996-61580	19960605 <--
EP 831911	A2	19980401	EP 1996-919173	19960605 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1192696	A	19980909	CN 1996-196086	19960605 <--
BR 9608505	A	19990706	BR 1996-8505	19960605 <--
JP 11509838	T2	19990831	JP 1996-501683	19960605 <--
AT 216261	E	20020515	AT 1996-919173	19960605 <--
PT 831911	T	20020930	PT 1996-919173	19960605 <--
ES 2175098	T3	20021116	ES 1996-919173	19960605 <--
CZ 291268	B6	20030115	CZ 1997-3848	19960605 <--
IL 122246	A1	20040601	IL 1996-122246	19960605 <--
US 2004102423	A1	20040527	US 2002-271362	20021015 <--
PRIORITY APPLN. INFO.:			US 1995-486089 A	19950607 <--
			WO 1996-US9342 W	19960605 <--
			US 1996-773383 B1	19961226 <--
			US 1997-977409 B1	19971124 <--
			US 1999-415043 B1	19991007

OTHER SOURCE(S): MARPAT 126:152804
AB A combination therapy is disclosed which comprises a therapeutically-

effective amount of an epoxy-free spirolactone-type aldosterone receptor antagonist and a therapeutically-effective amount of an angiotensin II receptor antagonist for treatment of circulatory disorders, including cardiovascular disorders, e.g. **hypertension** and congestive heart failure. Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. A preferred epoxy-free spirolactone-type aldosterone receptor antagonist is spironolactone. A preferred combination therapy includes the angiotensin II receptor antagonist 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole and the aldosterone receptor antagonist spironolactone.

IT **133085-33-3**, BIBS39
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(spironolactone or other epoxy-free spirolactone-type aldosterone receptor antagonist in combination with angiotensin II antagonist for treatment of circulatory and cardiovascular disorders, including congestive heart failure)

RN 133085-33-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-6-[[(cyclohexylamino)carbonyl]amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 25 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:168547 HCAPLUS
DOCUMENT NUMBER: 126:152803
TITLE: Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive heart failure
INVENTOR(S): Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Alexander, John C.; Schuh, Joseph R.; Gorczynski, Richard J.
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640257	A1	19961219	WO 1996-US9335	19960605 <--

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,

LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA

CA 2224079	AA	19961219	CA 1996-2224079	19960605	<--
AU 9661577	A1	19961230	AU 1996-61577	19960605	<--
AU 725689	B2	20001019			
EP 831910	A1	19980401	EP 1996-919170	19960605	<--
EP 831910	B1	20011121			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
CN 1192697	A	19980909	CN 1996-196155	19960605	<--
BR 9609066	A	19990126	BR 1996-9066	19960605	<--
JP 11507627	T2	19990706	JP 1996-501678	19960605	<--
NZ 310730	A	20010126	NZ 1996-310730	19960605	<--
RU 2166330	C2	20010510	RU 1998-100250	19960605	<--
IL 122242	A1	20010724	IL 1996-122242	19960605	<--
AT 209047	E	20011215	AT 1996-919170	19960605	<--
ES 2167571	T3	20020516	ES 1996-919170	19960605	<--
PT 831910	T	20020531	PT 1996-919170	19960605	<--
RO 118046	B1	20030130	RO 1997-2272	19960605	<--
PL 185150	B1	20030331	PL 1996-324001	19960605	<--
CN 1522701	A	20040825	CN 2004-10002796	19960605	<--
US 6653306	B1	20031125	US 1997-781786	19970109	<--
NO 9705741	A	19980129	NO 1997-5741	19971205	<--
PRIORITY APPLN. INFO.:			US 1995-486456 A	19950607	<--
			WO 1996-US9335 W	19960605	<--

OTHER SOURCE(S): MARPAT 126:152803

AB A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of an angiotensin II receptor antagonist is described for treatment of circulatory disorders, including cardiovascular disorders, e.g. **hypertension** and congestive heart failure. Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of 9α,11α-substituted epoxy moiety. A preferred combination therapy includes the angiotensin II receptor antagonist 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl]-1H-tetrazole and the aldosterone receptor antagonist epoxymexrenone.

IT **133085-33-3**, BIBS39
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of cardiovascular disorders, including congestive heart failure)

RN 133085-33-3 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-6-[[(cyclohexylamino)carbonyl]amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 26 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:109382 HCAPLUS
DOCUMENT NUMBER: 126:140212
TITLE: Vascular endothelial growth factor in pulmonary **hypertension**
AUTHOR(S): Voelkel, Norbert F.; Hoeper, Marius; Maloney, James; Tuder, Rubin M.
CORPORATE SOURCE: Pulmonary Hypertension Center and Department of Pathology, University of Colorado Health Sciences Center, Denver, CO, 80262, USA
SOURCE: Annals of the New York Academy of Sciences (**1996**), 796(Cytokines and Adhesion Molecules in Lung Inflammation), 186-193
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study deals with several aspect of hypoxic pulmonary **hypertension** and begins to examine how the lung VEGF gene is regulated and whether a pharmacol. inhibitor of VEGF affects the development of hypoxia-induced pulmonary expression in a rat model. Results indicate that the gene encoding VEGF is upregulated by hypoxia, the stable prostacyclin analog iloprost, and by cAMP. Suramin, which inhibits growth factor receptor binding, antagonized the development of chronic hypoxic pulmonary **hypertension** in rats.

IT **145-63-1**, Suramin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VEGF in hypoxic pulmonary **hypertension**)

RN 145-63-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 27 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:97729 HCAPLUS
DOCUMENT NUMBER: 126:171477
TITLE: Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming F.; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 247,072. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594021	A	19970114	US 1995-477223	19950606 <--
US 5464853	A	19951107	US 1993-142159	19931021 <--
US 5514691	A	19960507	US 1993-142552	19931021 <--
US 5591761	A	19970107	US 1994-222287	19940405 <--
US 5571821	A	19961105	US 1994-247072	19940520 <--
CA 2217169	AA	19961010	CA 1996-2217169	19960404 <--
CA 2217169	C	20050329		
CA 2420614	AA	19961010	CA 1996-2420614	19960404 <--
WO 9631492	A1	19961010	WO 1996-US4759	19960404 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9655367	A1	19961023	AU 1996-55367	19960404 <--
AU 711968	B2	19991028		
EP 819125	A1	19980121	EP 1996-912600	19960404 <--
EP 819125	B1	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1184470	A	19980610	CN 1996-193973	19960404 <--
CN 1130355	B	20031210		
JP 11507015	T2	19990622	JP 1996-530524	19960404 <--
JP 3233642	B2	20011126		
NZ 306734	A	20000128	NZ 1996-306734	19960404 <--
NZ 500282	A	20000128	NZ 1996-500282	19960404 <--
EP 1048657	A1	20001102	EP 2000-113076	19960404 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2002030075	A2	20020129	JP 2001-171692	19960404 <--
JP 3527217	B2	20040517		
CA 2288439	C	20030401	CA 1996-2288439	19960404 <--
CA 2288439	AA	19961010		
AT 243203	E	20030715	AT 1996-912600	19960404 <--
PT 819125	T	20031128	PT 1996-912600	19960404 <--
ES 2201181	T3	20040316	ES 1996-912600	19960404 <--
PL 186854	B1	20040331	PL 1996-322707	19960404 <--
US 5962490	A	19991005	US 1996-721183	19960927 <--
TW 492966	B	20020701	TW 1996-85112218	19961004 <--
NO 9704577	A	19971204	NO 1997-4577	19971003 <--
NO 315607	B1	20030929		
MX 9707630	A	20000331	MX 1997-7630	19971003 <--
HK 1001769	A1	20040130	HK 1998-100844	19980205 <--
US 6331637	B1	20011218	US 1999-274280	19990322 <--
AU 9935803	A1	19990916	AU 1999-35803	19990622 <--
AU 726595	B2	20001116		
US 2002095041	A1	20020718	US 2001-6256	20011204 <--
US 6613804	B2	20030902		
JP 2004043495	A2	20040212	JP 2003-318261	20030910 <--
PRIORITY APPLN. INFO.:			US 1993-65202	B2 19930520 <--
			US 1993-100125	B2 19930730 <--
			US 1993-100565	B2 19930730 <--
			US 1993-142159	A2 19931021 <--
			US 1993-142552	A2 19931021 <--
			US 1993-142631	B2 19931021 <--
			US 1994-222287	A2 19940405 <--
			US 1994-247072	A2 19940520 <--

US 1995-417075	B2	19950404 <--
US 1987-100865	A2	19870925 <--
US 1990-416199	A2	19900515 <--
US 1995-416199	A	19950404 <--
US 1995-477223	A	19950606 <--
AU 1996-55367	A	19960404 <--
CA 1996-2217169	A3	19960404 <--
EP 1996-912600	A3	19960404 <--
JP 1996-530524	A3	19960404 <--
JP 2001-171692	A3	19960404 <--
WO 1996-US4759	W	19960404 <--
US 1996-721183	A1	19960927 <--
US 1997-913331	A3	19971107 <--

OTHER SOURCE(S): MARPAT 126:171477

GI



AB Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. The compds. include sulfonamides Ar2SO2NHAr1 [I; Ar1 = (un)substituted (cyclo)alk(en/yn)yl, aryl, heterocyclyl, bi- or tricyclyl; Ar2 = (un)substituted thienyl, furyl, pyrrolyl, benzothienyl, benzofuryl, indolyl]. In particular, N-(isoxazolyl) amides, and methods using them to inhibit binding of endothelin peptides to endothelin receptors, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more compds. I, or prodrugs thereof, are also provided. Over 160 synthetic examples and the results of a variety of bioassays are given. For instance, amidation of thiophene-2-sulfonyl chloride with 5-amino-4-bromo-3-methylisoxazole after treatment of the latter with NaH in dry THF gave 34% of the amide II. In an endothelin receptor assay, the amide III had IC50 values of 0.0006 μM and 1.99 μM at ETA and ETB receptors, resp.

IT **184035-57-2P 184035-67-4P 184035-68-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic sulfonamides as endothelin agonists and antagonists)

RN 184035-57-2 HCAPLUS

CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-67-4 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-68-5 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 28 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:97122 HCAPLUS
DOCUMENT NUMBER: 126:117992
TITLE: Dihydropyridine NPY antagonists: piperazine derivatives.
INVENTOR(S): Poindexter, Graham S.; Bruce, Marc; Johnson, Graham; Kozlowski, Michael; Leboulluec, Karen; Monkovic, Ivo; Seethala, Ramakrishna; Sloan, Charles P.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 747356	A1	19961211	EP 1996-109041	19960605 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5635503	A	19970603	US 1995-482355	19950607 <--
CA 2178413	AA	19961208	CA 1996-2178413	19960606 <--
AU 9654756	A1	19961219	AU 1996-54756	19960606 <--
AU 696241	B2	19980903		
JP 08337570	A2	19961224	JP 1996-145274	19960607 <--
PRIORITY APPLN. INFO.:			US 1995-482355 A	19950607 <--
OTHER SOURCE(S):	MARPAT 126:117992			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of non-peptide antagonists of NPY have been synthesized and are comprised of piperazine and homopiperazine derivs. of 4-phenyl-1,4-dihydropyridines, specifically I [R1 = lower alkyl; R2, R3 = cyano, lower alkyl; R4 = CO2R1, cyano, 3-methyl-1,2,4-oxadiazol-5-yl; R5 = H, halo, OH, alkyl, alkenyloxy, alkoxy; B = NH, bond; n = 2-5; m = 2, 3; R6 = alkyl, formyl, phenylalkyl, (un)substituted naphthyl or Ph] and their acid addition

salts and hydrates. As antagonists of NPY-induced feeding behavior, I are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders. I may also be useful in treating **hypertension**, depression, or anxiety. For example, 4-(3-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid di-Me ester underwent a sequence of: (1) hydrogenation of the nitro group (58%); (2) amidation of the resulting amine with 5-chlorovaleryl chloride (100%); and (3) coupling with 1-(7-methoxynaphthalen-1-yl)piperazine (54%), to give title compound II, isolated as the fumarate salt. The most preferred I had IC50 of <10 nM at NPY Y1 receptors in an in vitro assay using human neuroblastoma cell membranes.

IT **185998-26-9P 185998-27-0P 185998-28-1P**
185998-29-2P 185998-31-6P 185998-32-7P
185998-33-8P 185998-34-9P 185998-35-0P
185998-36-1P 185998-37-2P 185998-38-3P
185998-39-4P 185998-40-7P 185998-41-8P
185998-42-9P 185998-43-0P 185998-44-1P
185998-45-2P 185998-46-3P 185998-48-5P
185998-49-6P 185998-50-9P 185998-51-0P
185998-52-1P 185998-53-2P 185998-54-3P
185998-55-4P 185998-56-5P 185998-57-6P
185998-58-7P 185998-59-8P 185998-60-1P
185998-61-2P 185998-62-3P 185998-64-5P
185998-66-7P 185998-67-8P 185998-68-9P
185998-69-0P 185998-70-3P 185998-71-4P
185998-72-5P 185998-73-6P 185998-74-7P
185998-75-8P 185998-77-0P 185998-78-1P
185998-79-2P 185998-80-5P 185998-81-6P
185998-82-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyridine piperazine derivs. as NPY antagonists)

RN 185998-26-9 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2-methyl-6-propyl-, 5-ethyl 3-methyl ester, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl

RN 185998-27-0 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)



RN 185998-28-1 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-29-2 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, diethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-31-6 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl

ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-32-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 185998-33-8 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, butyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-34-9 HCAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, 1,1-dimethylethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-35-0 HCAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185998-36-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 185998-37-2 HCAPLUS
CN 3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 185998-38-3 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[4-chloro-3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-39-4 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[4-chloro-3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-40-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]-4-(2-propenyloxy)phenyl]-2,6-

dimethyl-, dimethyl ester, hydrochloride (10:13) (9CI) (CA INDEX NAME)



●13/10 HCl

RN 185998-41-8 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]-4-(2-propenyloxy)phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 185998-42-9 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[4-hydroxy-3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 185998-43-0 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[4-hydroxy-3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185998-44-1 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-45-2 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-46-3 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(2-phenoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, dimethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-48-5 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[hexahydro-4-(2-methoxyphenyl)-1H-1,4-diazepin-1-yl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, dimethyl ester, hydrochloride (2:3) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●3/2 HCl

RN 185998-49-6 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(phenylmethyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-50-9 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-(4-phenyl-1-piperazinyl)propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-51-0 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-52-1 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(4-methylphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-53-2 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-(4-chlorophenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-54-3 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-(3,4-dichlorophenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-55-4 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(4-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-56-5 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-[2-(2-propenyloxy)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-57-6 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(2-propoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-58-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-59-8 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-60-1 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 185998-59-8
CMF C32 H41 N5 O6



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 185998-61-2 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-62-3 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-(4-aminophenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-64-5 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-[2-(methoxycarbonyl)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185998-63-4
CMF C34 H43 N5 O7



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 185998-66-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-[2-amino-4-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185998-65-6
CMF C33 H41 F3 N6 O5



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 185998-67-8 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-[2-(formylamino)-4-(trifluoromethyl)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185998-68-9 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185998-69-0 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-70-3 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 185998-71-4 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(2-methylphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-72-5 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-(4-chlorophenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-73-6 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[4-[[[[3-[4-[2-(2-propenyloxy)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-74-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[4-[[[[3-[4-(2-propoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-75-8 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[4-[[[[3-[4-(2-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-77-0 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-hydroxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 185998-78-1 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-(4-aminophenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-79-2 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[4-[2-(ethoxycarbonyl)phenyl]-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 185998-80-5 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 185998-81-6 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 4-[3-[[[[3-[hexahydro-4-(2-methoxyphenyl)-1H-1,4-diazepin-1-yl]propyl]amino]carbonyl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 185998-82-7 HCAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[3-[[[[3-[4-(2-phenoxyphenyl)-1-piperazinyl]propyl]amino]carbonyl]amino]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 29 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:14802 HCAPLUS

DOCUMENT NUMBER: 126:47124
TITLE: Preparation of 4-aminobenzazepine derivatives as inhibitors of neutral endopeptidase and angiotensin I-converting enzyme
INVENTOR(S): Oinuma, Hitoshi; Suda, Shinji; Yoneda, Naoki; Kotake, Makoto; Matsushima, Tomohiro; Saito, Mamoru; Matsuoka, Toshuki; Adachi, Hideyuki; Namiki, Masayuki; Sudo, Takeshi
PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08277271	A2	19961022	JP 1995-81544	19950406 <--
PRIORITY APPLN. INFO.:			JP 1995-81544	19950406 <--

OTHER SOURCE(S): MARPAT 126:47124
GI



I



II

Q=



Q1=



AB The title compds. [I; R1 = H, acyl; R2 = H, HO2C-protecting group; R3 = H, lower alkyl, cycloalkyl, (un)substituted aryl, heteroaryl, or arylalkyl; R4 , R5 = H, lower alkyl, acyl, alkylsulfonyl, (un)substituted arylsulfonyl, C(:Y)NR6R7; wherein R6, R7 = H, lower alkyl, (un)substituted aryl or heteroaryl; or NR6R7 forms a ring; Y = O, S; l, m, and n are not defined] or pharmacol. acceptable salts thereof, which are also

antagonists of vasopressin receptors, are prepared (A) a preventive or remedy of diseases, in particular heart failure or **hypertension**, affected by neutral endopeptidase- or angiotensin I-converting enzyme inhibiting activity or (b) a natriuretic agent containing said compound I. is claimed. These compds. possess both neutral endopeptidase-inhibiting and angiotensin I-converting enzyme-inhibiting activity, can orally be administered, have good metabolic stability and low toxicity, are suitable for long term administration to patients suffering from **hypertension** and heart failure. Thus, 3-aminobenzazepine derivative (II; R = H, R2 = Et, R4 = SO2Me) (preparation given) was condensed with (2S)-acetylthio-3-phenylpropionic acid using 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in CH2Cl2 overnight to give 75% II (R = Q, R1 = Ac, R2 = Et, R4 = SO2Me), which was treated with NaOH in aqueous EtOH at room temperature for 2 h under N and acidified with 1N aqueous HCl to give 71% II (R = Q, R1 = R2 = H, R4 = SO2Me). II (R = Q1, R2 = Et, R4 = SO2Me) in vitro showed IC50 of 12 and 9 nM against neutral endopeptidase and angiotensin I-converting enzyme, resp.

IT **184885-36-7P 184885-37-8P 184885-38-9P**
184885-43-6P 184885-45-8P 184885-48-1P
184885-49-2P 184885-51-6P 184885-55-0P
184885-56-1P 184885-57-2P 184885-59-4P
184885-61-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzazepine derivs. as inhibitors of neutral endopeptidase and angiotensin I-converting enzyme for disease treatment or prevention)

RN 184885-36-7 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-amino-2,3,4,5-tetrahydro-7-[[(methylamino)carbonyl]amino]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 184885-37-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-amino-7-[[(ethylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 184885-38-9 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-amino-7-[[(butylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 184885-43-6 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[2-(acetylthio)-3-methyl-1-oxobutyl]amino]-2,3,4,5-tetrahydro-7-[[(methylamino)carbonyl]amino]-2-oxo-, ethyl ester, [3(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-45-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[2-(acetylthio)-3-methyl-1-oxopentyl]amino]-2,3,4,5-tetrahydro-7-[[(methylamino)carbonyl]amino]-2-oxo-, ethyl ester, [3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-48-1 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[2-(acetylthio)-3-methyl-1-oxopentyl]amino]-7-[[(ethylamino)carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-

, ethyl ester, [3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-49-2 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[2-(acetylthio)-3-methyl-1-oxopentyl]amino]-2,3,4,5-tetrahydro-2-oxo-7-[[(phenylamino)carbonyl]amino]-, ethyl ester, [3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-51-6 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-[[2-(acetylthio)-3-methyl-1-oxopentyl]amino]-7-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, ethyl ester, [3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-55-0 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 2,3,4,5-tetrahydro-3-[(2-mercapto-3-methyl-

1-oxopentyl)amino]-2-oxo-7-[[(phenylamino)carbonyl]amino]-,
[3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-56-1 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 7-[[[(1,1-dimethylethyl)amino]carbonyl]ami
no]-2,3,4,5-tetrahydro-3-[(2-mercapto-3-methyl-1-oxopentyl)amino]-2-oxo-,
[3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-57-2 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 2,3,4,5-tetrahydro-3-[(2-mercapto-3-methyl-
1-oxopentyl)amino]-7-[[(methylamino)carbonyl]amino]-2-oxo-,
[3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-59-4 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 7-[[(ethylamino)carbonyl]amino]-2,3,4,5-
tetrahydro-3-[(2-mercapto-3-methyl-1-oxopentyl)amino]-2-oxo-,
[3(2S,3S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184885-61-8 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 2,3,4,5-tetrahydro-3-[(2-mercapto-3-methyl-1-oxobutyl)amino]-7-[[(methylamino)carbonyl]amino]-2-oxo-, [3(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **184885-69-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminobenzazepine derivs. as inhibitors of neutral endopeptidase and angiotensin I-converting enzyme for disease treatment or prevention)
RN 184885-69-6 HCAPLUS
CN 1H-1-Benzazepine-1-acetic acid, 3-azido-2,3,4,5-tetrahydro-7-[[(methylamino)carbonyl]amino]-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 30 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:761669 HCAPLUS
DOCUMENT NUMBER: 126:31342
TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin receptor antagonists
INVENTOR(S): Chan, Ming Fai; Raju, Bore Gowda; Kois, Adam; Verner, Erik Joel; Wu, Chengde; Castillo, Rosario Silverstre; Yalamoori, Venkatachalapathi; Balaji, Vitukudi Narayanaiyenga

PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9631492	A1	19961010	WO 1996-US4759	19960404 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5594021	A	19970114	US 1995-477223	19950606 <--
AU 9655367	A1	19961023	AU 1996-55367	19960404 <--
AU 711968	B2	19991028		
EP 819125	A1	19980121	EP 1996-912600	19960404 <--
EP 819125	B1	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9604875	A	19980519	BR 1996-4875	19960404 <--
JP 11507015	T2	19990622	JP 1996-530524	19960404 <--
JP 3233642	B2	20011126		
NZ 306734	A	20000128	NZ 1996-306734	19960404 <--
AT 243203	E	20030715	AT 1996-912600	19960404 <--
PL 186854	B1	20040331	PL 1996-322707	19960404 <--
US 5962490	A	19991005	US 1996-721183	19960927 <--
NO 9704577	A	19971204	NO 1997-4577	19971003 <--
NO 315607	B1	20030929		
MX 9707630	A	20000331	MX 1997-7630	19971003 <--
US 2001021714	A1	20010913	US 1997-913331	19971107 <--
US 6342610	B2	20020129		
HK 1001769	A1	20040130	HK 1998-100844	19980205 <--
US 6331637	B1	20011218	US 1999-274280	19990322 <--
AU 9935803	A1	19990916	AU 1999-35803	19990622 <--
AU 726595	B2	20001116		
US 2002091272	A1	20020711	US 2001-11610	20011105 <--
US 6632829	B2	20031014		

PRIORITY APPLN. INFO.:		
US 1995-416199	A	19950404 <--
US 1995-417075	A	19950404 <--
US 1995-477223	A	19950606 <--
US 1987-100865	A2	19870925 <--
US 1990-416199	A2	19900515 <--
US 1993-65202	B2	19930520 <--
US 1993-100125	B2	19930730 <--
US 1993-100565	B2	19930730 <--
US 1993-142159	A2	19931021 <--
US 1993-142552	A2	19931021 <--
US 1993-142631	B2	19931021 <--
US 1994-222287	A2	19940405 <--
US 1994-247072	A2	19940520 <--
AU 1996-55367	A	19960404 <--
WO 1996-US4759	W	19960404 <--
US 1996-721183	A1	19960927 <--
US 1997-938325	A3	19970926 <--

OTHER SOURCE(S): MARPAT 126:31342

GI



II

AB R2SO2NHR1 [I; R1 = (hetero)aryl; R2 = (un)substituted biphenylyl, -2- or -3-furyl, -thienyl, -pyrrolyl] were prepared Thus, 5-amino-4-bromo-3-methylisoxazole (preparation given) was amidated by thiophene-2-sulfonyl chloride to give title compound II. Data for biol. activity of I were given.

IT **184035-57-2P 184035-67-4P 184035-68-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin receptor antagonists)

RN 184035-57-2 HCAPLUS

CN 3-Thiophenesulfonamide, 2-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-67-4 HCAPLUS

CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 184035-68-5 HCAPLUS
CN 3-Thiophenesulfonamide, 2,2'-(carbonyldiimino)bis[N-(4-bromo-3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 31 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:751800 HCAPLUS
DOCUMENT NUMBER: 126:31225
TITLE: Preparation of 1H-pyrazolo[3,4-d]pyrimidin-4-one derivatives as phosphodiesterase inhibitors
INVENTOR(S): Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka; Hatayama, Katsuo; Tomizawa, Kazuyuki
PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253484	A2	19961001	JP 1996-5930	19960117 <--
JP 3713783	B2	20051109		

PRIORITY APPLN. INFO.: JP 1995-6986 A 19950120 <--
OTHER SOURCE(S): MARPAT 126:31225
GI



I

AB Title compds. I [R1 = C1-4 alkyl; X = phenoxy, NR2R3; R2, R3 = H, C2-4 hydroxyalkyl, or NR2R3 = morpholino, piperidino, etc.], phosphodiesterase inhibitors and therefore useful for treatment of **hypertension** and other cardiovascular diseases, (no data), are prepared Thus, I [R1 = Pr, X = PhO] was prepared from 6-(5-amino-2-propoxyphenyl)-4,5-dihydro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-one (preparation given) and Ph chloroformate. This was further reacted with morpholine to give I [R1 = Pr, X = morpholino]. In an in vitro study, this had an IC50 of 2.4 μM against phosphodiesterase.

IT **184356-80-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-pyrazolo[d]pyrimidinone derivs. as phosphodiesterase inhibitors)

RN 184356-80-7 HCAPLUS

CN Urea, N-[3-(4,5-dihydro-1,3-dimethyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-ethoxyphenyl]-N'-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 32 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:746234 HCAPLUS
DOCUMENT NUMBER: 126:18786
TITLE: Indole derivatives as cGMP-PDE inhibitors
INVENTOR(S): Oku, Teruo; Sawada, Kozo; Kuroda, Akio; Ohne, Kazuhiko; Nomoto, Atsushi; Hosogai, Naomi; Nakajima, Yoshimitsu; Nagashima, Akira; Sogabe, Keizo; Amura, Kouichi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Ltd., Japan
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632379	A1	19961017	WO 1996-JP892	19960402 <--
CA 2217707	AA	19961017	CA 1996-2217707	19960402 <--
AU 9651234	A1	19961030	AU 1996-51234	19960402 <--
AU 713460	B2	19991202		
EP 820441	A1	19980128	EP 1996-907750	19960402 <--
EP 820441	B1	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1187812	A	19980715	CN 1996-194691	19960402 <--
JP 11503445	T2	19990326	JP 1996-530864	19960402 <--
AT 219765	E	20020715	AT 1996-907750	19960402 <--
ES 2175079	T3	20021116	ES 1996-907750	19960402 <--
ZA 9602859	A	19961011	ZA 1996-2859	19960410 <--
TW 420663	B	20010201	TW 1996-85104519	19960416 <--
US 6069156	A	20000530	US 1997-930597	19971210 <--
PRIORITY APPLN. INFO.:			GB 1995-7432 A	19950410 <--
			GB 1995-12560 A	19950621 <--
			GB 1995-16136 A	19950807 <--
			AU 1996-8294 A	19960227 <--
			WO 1996-JP892 W	19960402 <--

OTHER SOURCE(S): MARPAT 126:18786
GI



I



II

AB The invention relates to new indole derivs. I and their pharmaceutically acceptable salts [wherein R1 = H, halo, NO2, CO2H, protected CO2H, acyl, (un)substituted alk(en)yl, etc.; R2 = H, halo, alkenyl, acyl, (un)substituted alkyl, etc.; R3 = (un)substituted alk(en)yl where the substituent is oxo, (un)substituted aryl, or heterocyclyl; R4 = CO2H, protected CO2H, acyl, cyano, amino, halo, etc.; R1 and R2 may form 4- to 7-membered carboxylic ring (un)substituted with oxo]. I are cyclic nucleotide-PDE inhibitors (specifically cGMP-PDE), and are useful for treating and preventing a variety of conditions, including angina, **hypertension**, renal failure, atherosclerosis, stroke, asthma, impotence, diabetic complications, and glaucoma. Almost 300 compds. I and

numerous intermediates were prepared For example, Me 3-isobutyryl-2-propylindole-6-carboxylate (preparation given) was N-benzylated by 2-chlorobenzyl bromide using NaH in DMF. The product underwent saponification with NaOH in aqueous EtOH, followed by amidation of the resultant acid using EDC, HOBt, and aqueous NH3, to give title amide II. II inhibited human platelet cGMP-PDE in vitro with IC50 <100 nM. I were also active in a variety of other bioassays, including relaxation of isolated rat aorta, inhibition of vascular smooth muscle cell proliferation, inhibition of vasopressin-induced vasospasm, the cyclosporin and FK506 nephritis models, the diabetic glomerulosclerosis model, and several animal impotence models.

IT **184149-09-5P 184149-24-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as cGMP-PDE inhibitors)

RN 184149-09-5 HCAPLUS
CN Urea, N-[1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-6-yl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 184149-24-4 HCAPLUS
CN 1H-Indole-6-carboxamide, 1-[[2-[[(methylamino)carbonyl]amino]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)



L18 ANSWER 33 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:719042 HCAPLUS
DOCUMENT NUMBER: 126:31352
TITLE: Preparation of 7-(2-imidazolylimino)quinolines useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Cupps, Thomas L.; Bogdan, Sophie E.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 169,342,abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5576437	A	19961119	US 1994-292672	19940818 <--
BR 9408344	A	19970819	BR 1994-8344	19941207 <--
CA 2179011	AA	19950803	CA 1994-2179011	19941215 <--
CA 2179011	C	19991130		
WO 9520386	A1	19950803	WO 1994-US14290	19941215 <--
W: AM, AU, BB, BG, BR, BY, CA, CH, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9513394	A1	19950815	AU 1995-13394	19941215 <--
AU 704857	B2	19990506		
EP 734261	A1	19961002	EP 1995-904886	19941215 <--
EP 734261	B1	20010627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1137754	A	19961211	CN 1994-194533	19941215 <--
CN 1085945	B	20020605		
HU 76278	A2	19970728	HU 1996-1661	19941215 <--
HU 219494	B	20010428		
CZ 285990	B6	19991215	CZ 1996-1752	19941215 <--
PL 178054	B1	20000229	PL 1994-315058	19941215 <--
RU 2161967	C2	20010120	RU 1996-115140	19941215 <--
NZ 333369	A	20010427	NZ 1994-333369	19941215 <--
AT 202475	E	20010715	AT 1995-904886	19941215 <--
ES 2158076	T3	20010901	ES 1995-904886	19941215 <--
TW 406077	B	20000921	TW 1995-84102758	19950322 <--
US 5716966	A	19980210	US 1995-496796	19950629 <--
FI 9602492	A	19960725	FI 1996-2492	19960614 <--
NO 9602537	A	19960814	NO 1996-2537	19960614 <--
NO 311749	B1	20020121		
GR 3036199	T3	20011031	GR 2001-401047	20010711 <--

PRIORITY APPLN. INFO.:
US 1993-169342 B2 19931217 <--
US 1994-292672 A 19940818 <--
WO 1994-US14290 W 19941215 <--

OTHER SOURCE(S): MARPAT 126:31352
GI



I

AB The title compds. (I; R = C1-3 alkyl or alkenyl; R1 = H, F, CN), useful as alpha-2 adrenoceptor agonists for treating nasal congestion, ocular **hypertension** or glaucoma, and/or gastrointestinal disorders, are prepared and I-containing formulations presented. Thus, the dihydrochloride salt of I (R = Me, R1 = H) was prepared from 8-methyl-7-nitroquinoline in 6 steps.

IT **168770-36-3P 168770-37-4P 168770-40-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 7-(2-imidazolylimino)quinolines useful as alpha-2 adrenoceptor agonists)

RN 168770-36-3 HCAPLUS
CN Thiourea, N-(2-aminoethyl)-N'-(5-cyano-8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 168770-37-4 HCAPLUS
CN Thiourea, N-(2-aminoethyl)-N'-(5-fluoro-8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 168770-40-9 HCAPLUS
CN Thiourea, N-(2-aminoethyl)-N'-(8-methyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 34 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:716990 HCAPLUS
DOCUMENT NUMBER: 126:47207
TITLE: Preparation of N-isoxazolyl(hetero)arenesulfonamides as endothelin receptor antagonists

INVENTOR(S): Chan, Ming Fai; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.; Ramnarayan, Kalyanaraman
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 67 pp., Cont.-in-part of U.S. Ser. No. 222,287.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5571821	A	19961105	US 1994-247072	19940520 <--
US 5464853	A	19951107	US 1993-142159	19931021 <--
US 5514691	A	19960507	US 1993-142552	19931021 <--
US 5591761	A	19970107	US 1994-222287	19940405 <--
US 5594021	A	19970114	US 1995-477223	19950606 <--
US 5962490	A	19991005	US 1996-721183	19960927 <--
US 6030991	A	20000229	US 1996-730633	19961206 <--
US 6331637	B1	20011218	US 1999-274280	19990322 <--
AU 9935803	A1	19990916	AU 1999-35803	19990622 <--
AU 726595	B2	20001116		
US 6376523	B1	20020423	US 1999-439802	19991112 <--
US 2001036958	A1	20011101	US 2000-749716	20001227 <--
US 6541498	B2	20030401		
US 2002095041	A1	20020718	US 2001-6256	20011204 <--
US 6613804	B2	20030902		

PRIORITY APPLN. INFO.:

US 1993-65202	B2	19930520 <--
US 1993-100125	B2	19930730 <--
US 1993-100565	B2	19930730 <--
US 1993-142159	A2	19931021 <--
US 1993-142552	A2	19931021 <--
US 1993-142631	B2	19931021 <--
US 1994-222287	A2	19940405 <--
US 1987-100865	A2	19870925 <--
US 1990-416199	A2	19900515 <--
US 1994-247072	A2	19940520 <--
US 1995-416199	B1	19950404 <--
US 1995-417075	B2	19950404 <--
US 1995-477223	A2	19950606 <--
AU 1996-55367	A	19960404 <--
WO 1996-US4759	A2	19960404 <--
US 1996-721183	A1	19960927 <--
US 1996-730633	A1	19961206 <--
US 1997-913331	A3	19971107 <--
US 1999-439802	A1	19991112

OTHER SOURCE(S): MARPAT 126:47207
GI



II

AB R1SO2NHR2 [I; R1,R2 = (cyclo)alkyl, (un)substituted (hetero)aryl] were prepared Thus, 5-amino-4-bromo-3-methylisoxazole (preparation given) was amidated by thiophene-2-sulfonyl chloride to give title compound II. Data for biol. activity of I were given.

IT **166963-50-4P 166963-51-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolyl(hetero)arenesulfonamides as endothelin receptor antagonists)

RN 166963-50-4 HCAPLUS

CN Glycine, N-[[[4-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 166963-51-5 HCAPLUS

CN Benzenesulfonamide, 4-[[(cyclohexylamino)carbonyl]amino]-N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L18 ANSWER 35 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:637686 HCAPLUS
DOCUMENT NUMBER: 125:328289
TITLE: Phenoxyphenylacetic acids and derivatives useful as endothelin antagonists
INVENTOR(S): Bagley, Scott W.; Broten, Theodore P.; Chakravarty, Prasun K.; Dhanoa, Daljit S.; Fitch, Kenneth J.; Greenlee, William J.; Kevin, Nancy J.; Pettibone, Douglas J.; Rivero, Ralph A.; et al.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 287,374, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5565485	A	19961015	US 1994-294232	19940822	<--
JP 08508034	T2	19960827	JP 1994-521226	19940317	<--
PL 175786	B1	19990226	PL 1994-310661	19940317	<--
RU 2139273	C1	19991010	RU 1995-121625	19940317	<--
ZA 9401923	A	19941014	ZA 1994-1923	19940318	<--
CA 2195758	AA	19960222	CA 1995-2195758	19950807	<--
WO 9604905	A1	19960222	WO 1995-US9967	19950807	<--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, US, US, UZ					
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9532767	A1	19960307	AU 1995-32767	19950807	<--
AU 705881	B2	19990603			
EP 774965	A1	19970528	EP 1995-929396	19950807	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 10503779	T2	19980407	JP 1995-507425	19950807	<--
FI 9504404	A	19950918	FI 1995-4404	19950918	<--
NO 9503672	A	19951117	NO 1995-3672	19950918	<--
US 5668176	A	19970916	US 1996-733536	19961018	<--
PRIORITY APPLN. INFO.:			US 1993-34455	B2 19930319	<--
			US 1994-197467	B2 19940224	<--
			US 1994-287374	B2 19940808	<--
			WO 1994-US2871	W 19940317	<--
			US 1994-294232	A 19940822	<--
			US 1995-473172	A 19950607	<--
			WO 1995-US9967	W 19950807	<--

OTHER SOURCE(S): MARPAT 125:328289

GI



I II

AB Phenoxyphenylacetic acids and derivs. of the general structural formula I wherein: R3a and R3b are independently, e.g., H, halo, NO2; R1 and R2 on adjacent C atoms are joined together to form a ring structure -A- where A represents, e.g., YCR4:CR5, CR4:CR5Y, CR6R6CR6R6Y; Y is O or SOn, n is 0, 1, or 2; R4 and R5 are independently, e.g., H, (un)substituted C1-6 alkyl, C2-6 alkenyl; R6 is, e.g., H, (un)substituted C1-4 alkyl; R8 is, e.g., H, (un)substituted C1-6 alkyl; R9 and R10 are independently, e.g., H, C1-6 alkyl, unsubstituted or substituted with C3-7 cycloalkyl or CO2R7, R7 is,

e.g., H, C1-6 alkyl, Ph; or R9 and R10 on adjacent carbons can join together to form a fused (un)substituted Ph ring; R12 is, e.g., H, (un)substituted C1-6 alkyl; X is e.g., O, SOn, NR7; Z is, e.g., CO2H, CO2R13, CONH-(tetrazol-5-yl); R13 is, e.g., C1-4 alkyl, CHR14OCOR15; R14 and R15 are independently C1-6 alkyl or Ph; (with provisos) have endothelin antagonist activity (IC50 < 50 μM) and are useful in treating cardiovascular disorders, such as **hypertension**, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma. Thus, e.g., alkylation of Me 4-hydroxy-3-n-propylbenzoate with Et α-bromo-3,4-methylenedioxyphenylacetate afforded Et α-(4-carbomethoxy-2-n-propylphenoxy)-3,4-methylenedioxyphenylacetate; saponification of the latter afforded 94% α-(4-carbomethoxy-2-n-propylphenoxy)-3,4-methylenedioxyphenylacetic acid; coupling of the latter with 4-isopropylbenzenesulfonamide followed by saponification afforded N-(4-isopropylbenzenesulfonyl)-α-(4-carboxy-2-n-propylphenoxy)-3,4-methylenedioxyphenylacetamide dipotassium salt (II.2K) which inhibited the depressor and pressor effects of endothelin- 1 on diastolic blood pressure in dogs by 69 and 76%, resp.; the pressor effect on intraurethral pressure was inhibited 93%.

IT **177953-01-4P 177953-22-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenoxyphenylacetic acids and derivs. useful as endothelin antagonists)

RN 177953-01-4 HCAPLUS

CN 1,3-Benzodioxole-5-acetamide, α-[4-[[[(1-methylethyl)amino]carbonyl]amino]-2-propylphenoxy]-N-[[4-(1-methylethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 177953-22-9 HCAPLUS

CN Benzoic acid, 4-[1-(1,3-benzodioxol-5-yl)-2-[[[2,5-dimethoxy-4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]sulfonyl]amino]-2-oxoethoxy]-3-propyl- (9CI) (CA INDEX NAME)



IT **159591-56-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenoxyphenylacetic acids and derivs. useful as endothelin antagonists)
RN 159591-56-7 HCAPLUS
CN 1,3-Benzodioxole-5-acetic acid, α-[4-[[[(1-methylethyl)amino]carbonyl]amino]-2-propylphenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 36 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:625320 HCAPLUS
DOCUMENT NUMBER: 125:275909
TITLE: Preparation of hexahydropyrazinoquinoline derivatives exhibiting excellent serotonin 5-HT1A receptor agonist effects
INVENTOR(S): Kojima, Koichi; Aizawa, Yuichi; Samata, Naozumi; Sakai, Junichi; Koyama, Kazuo; Tonohiro, Toshiyuki; Sugimoto, Masahiko; Hara, Takao; Hisamoto, Marie; Homma, Hiroshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9623789	A1	19960808	WO 1996-JP194	19960201 <--
W: AU, CA, CN, CZ, FI, HU, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08269057	A2	19961015	JP 1996-13588	19960130 <--

AU 9645477 A1 19960821 AU 1996-45477 19960201 <--
PRIORITY APPLN. INFO.: JP 1995-16930 A 19950203 <--
WO 1996-JP194 W 19960201 <--
OTHER SOURCE(S): MARPAT 125:275909
GI



I





AB Hexahydropyrazinoquinoline derivs. having general formula [I; R = NR1R2, CONHR6; R1 = COR3 and R2 = H; wherein R3 = alkyl, cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, cycloalkylamino, optionally substituted arylamino, or optionally substituted heterocyclyl; or R1 and R2 form together with the nitrogen atom, to which they are bonded, optionally substituted 2,4-dioxothiazolidin-3-yl (Q) or phthalimido (Q1); wherein R4, R5 = H, alkyl; wherein R6 = optionally substituted C6-14 aryl; X = CH2 or O; m = 2-6], which also show excellent tranquilizing effect on nervous stress and inhibiting effect on hallucination and are useful as preventives or remedies for anxiety, depression, **hypertension**, schizophrenia, sleep disorder, migraine headache, sexual function disorder, motion sickness, dizziness, or symptoms in association with senile dementia, are prepared Thus, 332 mg 3-(4-aminobutyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2a]quinoline was dissolved in THF, treated dropwise with 165 μL Et3N and 160 μL 2,4-difluorobenzoyl chloride, and stirred at room temperature for 1 h to give, after silica gel chromatog. and treatment with HCl in EtOAc, I (X = CH2, m = 4, R3 = 2,4-difluorophenyl) (II). II in vitro strongly inhibited the binding of [3H]8-hydroxy-2-dipropylaminotetralin to a 5-HT1A receptor preparation from rat hippocampus. A hard capsule formulation containing II was described.

IT **182207-99-4P 182208-00-0P 182208-01-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hexahydropyrazinoquinoline derivs. as serotonin 5-HT1A receptor agonists for disease therapy)

RN 182207-99-4 HCAPLUS

CN Urea, N-cyclohexyl-N'-[4-(1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinolin-3-yl)butyl]- (9CI) (CA INDEX NAME)



RN 182208-00-0 HCAPLUS
CN Urea, N-[4-(1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinolin-3-yl)butyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 182208-01-1 HCAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[4-(1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinolin-3-yl)butyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 37 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:546613 HCAPLUS
DOCUMENT NUMBER: 125:266592
TITLE: Endothelin antagonists for use in pharmaceuticals
INVENTOR(S): Cody, Wayne L.; Doherty, Annette M.; Topliss, John G.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 44 pp., Cont.-in-part of U.S. Ser. No. 33,515,abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5550110	A	19960827	US 1994-269257	19940630 <--
HU 68862	A2	19950828	HU 1994-3017	19930416 <--
CA 2094576	AA	19931023	CA 1993-2094576	19930421 <--

CA 2190756	AA	19960111	CA 1995-2190756		19950405 <--
WO 9600738	A1	19960111	WO 1995-US4171		19950405 <--
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9522065	A1	19960125	AU 1995-22065		19950405 <--
EP 767801	A1	19970416	EP 1995-915024		19950405 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
JP 10502075	T2	19980224	JP 1995-503115		19950405 <--
PRIORITY APPLN. INFO.:			US 1992-872225	B2	19920422 <--
			US 1993-33515	B2	19930331 <--
			US 1994-269257	A	19940630 <--
			WO 1995-US4171	W	19950405 <--

OTHER SOURCE(S): MARPAT 125:266592

AB Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compns. of the same, which are useful in treating (no data) elevated levels of endothelin, acute and chronic renal failure, **hypertension**, myocardial infarction, metabolic, endocrinol., neurol. disorders especially cerebral vasospasm, stroke, and head injury, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary **hypertension**, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes.

IT **158711-92-3P 158711-93-4P 175594-30-6P 175594-31-7P 182308-66-3P 182308-67-4P 182310-02-7P 182310-04-9P**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(endothelin antagonists for use in pharmaceuticals)

RN 158711-92-3 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 158711-93-4 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-asparty]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-30-6 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(10,11-

dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-31-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 182308-66-3 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(2H-dibenzo[a,d]cycloheptен-2-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 182308-67-4 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(2H-dibenzo[a,d]cyclohepten-2-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 182310-02-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(2H-dibenzo[a,d]cyclohepten-2-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-alloisoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 182310-04-9 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(2H-dibenzo[a,d]cyclohepten-2-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-alloisoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L18 ANSWER 38 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:521154 HCAPLUS
DOCUMENT NUMBER: 125:168012
TITLE: Preparation of thieno[2,3-d]pyrimidin-4-one derivatives as cyclic GMP-specific phosphodiesterase inhibitors
INVENTOR(S): Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka; Hatayama, Katsuo
PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08143571	A2	19960604	JP 1995-179742	19950717 <--
PRIORITY APPLN. INFO.:			JP 1994-224408 A1	19940920 <--
OTHER SOURCE(S):	MARPAT 125:168012			

GI



I

AB The title compds. [I; R1 = C1-4 alkyl; X = NHCOR2; R2 = PhO, morpholino, piperidino, pyrrolidino, 4-carbethoxypiperidino, 4-(2-hydroxyethyl)piperazino, NR3R4 (R3, R4 = H, C1-4 alkyl, C2-4 hydroxyalkyl)], their salts, and their intermediates [I; X = NH2, NO2] are prepared These compds. are potential cyclic GMP-specific phosphodiesterase inhibitors for treatment of **hypertension**, myocardiopathy

diseases. Thus, 2-amino-4-methyl-3-carbamylthiophene was reacted with 5-nitro-2-propoxybenzoyl chloride in the presence of Et3N, then treated with KOH, followed with NaBH4, and reacted with ClCO2Ph and morpholine to give I [R1 = Pr; X = NHCOR2, R2 = morpholino], which showed IC50 of 3.5 nM against cyclic GMP-specific phosphodiesterases.

IT **180306-67-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of thieno[2,3-d]pyrimidin-4-one derivs. as cyclic GMP-specific phosphodiesterase inhibitors)

RN 180306-67-6 HCAPLUS

CN Urea, N-[3-(1,4-dihydro-5-methyl-4-oxothieno[2,3-d]pyrimidin-2-yl)-4-propoxyphenyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 39 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:467034 HCAPLUS

DOCUMENT NUMBER: 125:142780

TITLE: Substituted heterocyclic compounds as inhibitors of nitric oxide synthase

INVENTOR(S): Shah, Shrenik K.; Grant, Stephan K.; Maccoss, Malcolm; Shankaran, Kothandaraman; Qi, Hongbo; Guthikonda, Ravindra N.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9614842	A1	19960523	WO 1995-US14512	19951113 <--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9641496	A1	19960606	AU 1996-41496	19951113 <--
PRIORITY APPLN. INFO.:			US 1994-339618	A2 19941115 <--
			WO 1995-US14512	W 19951113 <--

OTHER SOURCE(S): MARPAT 125:142780

GI



I



II



III



IV

AB Oxazinamines, thiazinamines and pyrimidinamines, and their homologs I (X = N, S, O; n = 0-4; ; R1-R3 = alkyl, alkenyl, etc.; R4, R5 = H, alkyl, etc.) and 2-iminooxazines, 2-iminothiazines, 2-iminopyrimidines II (same X, n, R1-R5) were disclosed for the treatment of nitric oxide synthase-mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. Example compds. are 5,6-dihydro-4H-1,3-thiazin-2-amine (III) and 4,5,6,7-tetrahydro-1,3-thiazepin-2-amine (IV). These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acute respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, systemic lupus erythematosus (SLE), ocular conditions such as ocular **hypertension** and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. I are also useful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosuppressive agents and for preventing or reversing tolerance to opiates and diazepines.

IT **179116-12-2P 179116-13-3P 179116-14-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazinamine, thiazinamines and pyrimidinamines and homologs as nitric oxide synthase inhibitors)

RN 179116-12-2 HCAPLUS

CN Thiourea, N-[3-(diethylamino)propyl]-N'-(5,6-dihydro-4H-1,3-thiazin-2-yl)-(9CI) (CA INDEX NAME)



RN 179116-13-3 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 179116-14-4 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



IT **179116-33-7 179116-34-8 179116-35-9**
179116-36-0 179116-37-1 179116-38-2
179116-39-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of oxazinamine, thiazinamines and pyrimidinamines and homologs as nitric oxide synthase inhibitors)

RN 179116-33-7 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-methyl- (9CI) (CA INDEX NAME)



RN 179116-34-8 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-ethyl- (9CI) (CA INDEX NAME)



RN 179116-35-9 HCAPLUS

CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-propyl- (9CI) (CA INDEX NAME)



RN 179116-36-0 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 179116-37-1 HCAPLUS
CN Thiourea, N-butyl-N'-(5,6-dihydro-4H-1,3-thiazin-2-yl)- (9CI) (CA INDEX NAME)



RN 179116-38-2 HCAPLUS
CN Thiourea, N-cyclohexyl-N'-(5,6-dihydro-4H-1,3-thiazin-2-yl)- (9CI) (CA INDEX NAME)



RN 179116-39-3 HCAPLUS
CN Thiourea, N-(5,6-dihydro-4H-1,3-thiazin-2-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



IT **179115-99-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazinamine, thiazinamines and pyrimidinamines and homologs as nitric oxide synthase inhibitors)
RN 179115-99-2 HCAPLUS

CN Benzamide, N-[[[2-(bromomethyl)phenyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 40 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:377087 HCAPLUS
DOCUMENT NUMBER: 125:58490
TITLE: Preparation of phenoxyphenylacetic acid-derivative endothelin antagonists
INVENTOR(S): Bagley, Scott W.; Broten, Theodore P.; Chakravarty, Prasun K.; Dhanoa, Daljit S.; Fitch, Kenneth J.; Greenlee, William J.; Kevin, Nancy Jo; Kieczykowski, Gerard R.; Matthews, Jay M.; et al.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604905	A1	19960222	WO 1995-US9967	19950807 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, US, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5565485	A	19961015	US 1994-294232	19940822 <--
AU 9532767	A1	19960307	AU 1995-32767	19950807 <--
AU 705881	B2	19990603		
EP 774965	A1	19970528	EP 1995-929396	19950807 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10503779	T2	19980407	JP 1995-507425	19950807 <--

PRIORITY APPLN. INFO.:

US 1994-287374	A	19940808 <--
US 1994-294232	A	19940822 <--
US 1995-473172	A	19950607 <--
US 1993-34455	B2	19930319 <--
US 1994-197467	B2	19940224 <--
WO 1995-US9967	W	19950807 <--

AB Phenoxyphenylacetic acid derivs. [e.g., N-(4-isopropylbenzenesulfonyl)-α-(4-carboxy-2-propylphenoxy)-3,4-methylenedioxyphenylacetamide dipotassium salt], which have endothelin antagonist activity and are useful in treating cardiovascular disorders such as **hypertension** (no data), postischemic renal failure (no data), vasospasm (no data), cerebral and cardiac ischemia (no data), myocardial infarction (no data), endotoxic shock (no data), benign prostatic hyperplasia (no data), inflammatory diseases (no data), asthma (no data), etc. (no data), are prepared

IT **177953-01-4P 177953-22-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyphenylacetic acid-derivative endothelin antagonists)
RN 177953-01-4 HCAPLUS
CN 1,3-Benzodioxole-5-acetamide, α-[4-[[[(1-methylethyl)amino]carbonyl]amino]-2-propylphenoxy]-N-[[4-(1-methylethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 177953-22-9 HCAPLUS
CN Benzoic acid, 4-[1-(1,3-benzodioxol-5-yl)-2-[[[2,5-dimethoxy-4-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]sulfonyl]amino]-2-oxoethoxy]-3-propyl- (9CI) (CA INDEX NAME)



IT **159591-56-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenoxyphenylacetic acid-derivative endothelin antagonists)
RN 159591-56-7 HCAPLUS
CN 1,3-Benzodioxole-5-acetic acid, α-[4-[[[(1-methylethyl)amino]carbonyl]amino]-2-propylphenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 41 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:241535 HCAPLUS
DOCUMENT NUMBER: 124:290282
TITLE: Preparation of peptides as endothelin antagonists.
INVENTOR(S): Cody, Wayne Livingston; Doherty, Annette Marian; Topliss, John Gordon
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600738	A1	19960111	WO 1995-US4171	19950405 <--
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5550110	A	19960827	US 1994-269257	19940630 <--
AU 9522065	A1	19960125	AU 1995-22065	19950405 <--
EP 767801	A1	19970416	EP 1995-915024	19950405 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10502075	T2	19980224	JP 1995-503115	19950405 <--

PRIORITY APPLN. INFO.:
US 1994-269257 A 19940630 <--
US 1992-872225 B2 19920422 <--
US 1993-33515 B2 19930331 <--
WO 1995-US4171 W 19950405 <--

OTHER SOURCE(S): MARPAT 124:290282
GI



AB A1-A2-A3-A4-A5-A6 [A1 = Q1; R = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, fluorenylmethyl, amino; R1 = H, alkyl; Z = O, S, SO, SO2, imino, (CH2)n, CO, etc.; n = 0-4; A2 = null, NR1CR1[(CH2)nR4]CO; R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,

heteroaryl, amino, acyl, etc.; A3 = null, NR1CR1[(CH2)nR5]W; R5 = H, alkyl, aryl, heteroaryl, acyl; W = CO, C(R1)2; A4, A5 = null, NR1CR1[(CH2)nR6]CO; R6 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; A6 = NR1CR1[(CH2)nR7]R8; R7 = aryl, heteroaryl; R8 = CO2R1, OR1, CON(R1)2, CH2OR1], were prepared I are useful in treating elevated levels of endothelin, acute and chronic renal failure, **hypertension**, myocardial infarction, metabolic, endocrinol., and neurol. disorders especially cerebral vasospasm, stroke, and head injury, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary **hypertension**, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes. Thus, Ac-D-Bhg-Leu-Asp-Ile-Ile-Trp-OH, [Bhg = 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylglycine] prepared by solid phase synthesis using BOC-protected amino acids, inhibited [125I]-endothelin-1 binding to rabbit renal artery smooth muscle cells with IC50 = 0.0026 μM.

IT **158711-92-3P 158711-93-4P 158712-01-7P 158712-02-8P 175594-30-6P 175594-31-7P 175594-39-5P 175594-40-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as endothelin antagonists)

RN 158711-92-3 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 158711-93-4 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-asparty]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 158712-01-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(5H-

dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 158712-02-8 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-30-6 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-asparty]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-31-7 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-39-5 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-D-2-(5H-

dibenzo[a,d]cyclohepten-5-yl)glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 175594-40-8 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[D-2-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-[(methylamino)carbonyl]glycyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-N-methyl-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L18 ANSWER 42 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:161143 HCAPLUS
DOCUMENT NUMBER: 124:232494
TITLE: Preparation of diazepine derivatives as specific inhibitors of human renin
INVENTOR(S): Ichihara, Masato; Kawanami, Eiji; Shibazaki, Masayuki
PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07304755	A2	19951121	JP 1994-98481	19940512 <--
PRIORITY APPLN. INFO.:			JP 1994-98481	19940512 <--

OTHER SOURCE(S): MARPAT 124:232494
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; ring A = (un)substituted benzene or thiophene; R1 = H, alkyl, aralkyl; R2 = alkyl, aralkyl, (un)substituted Ph; L1 = bond, alkyl- or aralkyl-substituted alkylene; X = bond, CO, NHCO; R3 = aralkyl, cycloalkylalkyl; L2 = (CHOH)n, CONHCHR5; n = 1,2; wherein R5 = aralkyl,

cycloalkylalkyl; Y = Het, CH2-Het, CH2S-Het, CO2R4; wherein Het = (un)substituted 3- to 5-membered heterocyclyl containing 1-4 N atoms; R4 = H, alkyl], which have lasting effect and excellent absorbability through digestive tract, and are suitable for clin. administration and useful for the treatment and prevention of **hypertension**, in particular renin-angiotensin dependent **hypertension** (no data), are prepared Thus, 133 mg (3R)-3-amino-1-methyl-5-phenyl-2,3-dihydro-1H-benzodiazepin-2-one was dissolved in CH2Cl2, followed by adding 0.15 mL Et3N and carbonyldiimidazole, stirring the resulting mixture at room temperature for 1 h, and adding a solution of 322 mg (1S)-1-cyclohexylmethyl-2-hydroxy-3-[(1-methyl-5-tetrazolyl)thio]propylamine hydrochloride and 0.31 mL Et3N in CH2Cl2, and the resulting mixture was stirred at room temperature for 2 h to give, after silica gel chromatog., the title compound (II).

IT **174398-90-4P 174398-91-5P 174398-92-6P**
174398-93-7P 174398-94-8P 174398-95-9P
174398-97-1P 174398-98-2P 174399-04-3P
174399-05-4P 174399-06-5P 174399-07-6P
174399-08-7P 174399-09-8P 174399-10-1P
174512-01-7P 174512-02-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide-containing diazepine derivs. as specific inhibitors of human renin)

RN 174398-90-4 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]-N'-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, [3R-[3R*[1S*,2R*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174398-91-5 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)





RN 174398-92-6 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-4-(4-morpholinyl)butyl]-N'-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 174398-93-7 HCAPLUS
CN L-Leucine, N-[N-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-L-leucyl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174398-94-8 HCAPLUS
CN L-Phenylalanine, N-[N-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl)amino]carbonyl]-L-phenylalanyl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174398-95-9 HCAPLUS
CN L-Valine, N-[N-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-L-leucyl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174398-97-1 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-hydroxy-3-[(1-methyl-1H-tetrazol-5-yl)thio]propyl]-N'-[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 174398-98-2 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-hydroxy-3-[(1-methyl-1H-tetrazol-5-yl)thio]propyl]-N'-[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)



RN 174399-04-3 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[(1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 174399-05-4 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[(2,3-dihydro-2-oxo-5-phenyl-1-propyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)





RN 174399-06-5 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)





RN 174399-07-6 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[[2,3-dihydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 174399-08-7 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 174399-09-8 HCAPLUS
CN Cyclohexanebutanoic acid, β-[[[(7-ethyl-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-thieno[2,3-e]-1,4-diazepin-3-yl)amino]carbonyl]amino]-α-hydroxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)





RN 174399-10-1 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-hydroxy-3-[(1-methyl-1H-tetrazol-5-yl)thio]propyl]-N'-[2,3-dihydro-1-methyl-5-(4-methylphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 174512-01-7 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-hydroxy-3-[(1-methyl-1H-tetrazol-5-yl)thio]propyl]-N'-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 174512-02-8 HCAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]-N'-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, [3R-[3R*[1S*,2R*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 43 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:35000 HCAPLUS
DOCUMENT NUMBER: 124:232248
TITLE: Benzopyran derivatives having affinity for α1-adrenergic and 5HT1A-serotoninergic receptors
INVENTOR(S): Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Testa, Rodolfo
PATENT ASSIGNEE(S): Recordati S.A., Chemical and Pharmaceutical Company, Switz.
SOURCE: U.S., 37 pp. Cont.-in-part of U.S. 5,403,842.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5474994	A	19951212	US 1993-67861	19930526 <--
US 5403842	A	19950404	US 1992-888775	19920526 <--
EP 558245	A1	19930901	EP 1993-301264	19930222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 9336296	A1	19930913	AU 1993-36296	19930223 <--
RO 112111	B3	19970530	RO 1994-1404	19930223 <--
PL 175556	B1	19990129	PL 1993-304889	19930223 <--
SK 280143	B6	19990910	SK 1994-1007	19930223 <--
CN 1079738	A	19931222	CN 1993-105852	19930526 <--
CN 1040434	B	19981028		
FI 9403876	A	19940823	FI 1994-3876	19940823 <--
NO 9403140	A	19940825	NO 1994-3140	19940825 <--
US 5605896	A	19970225	US 1994-299188	19940831 <--
PRIORITY APPLN. INFO.:			US 1992-888775 A2	19920526 <--
			EP 1993-301264 A	19930222 <--
			IT 1992-MI408 A	19920225 <--
			WO 1993-EP420 A	19930223 <--
			US 1993-67861 A2	19930526 <--

OTHER SOURCE(S): MARPAT 124:232248
GI



I



II



III

AB This invention provides bicyclic heterocyclic derivs. I wherein the dotted line represents a single or double bond; X represents a nitrogen, oxygen or sulfur atom, or an amino or alkylamino group, a sulfinyl or sulfonyl group; W represents a carbonyl, thiocarbonyl, hydroxymethylene, or a methylene group or a bond; or when X is nitrogen and W is a methine, the fused rings represent a quinoline; R2 represents, e.g, a hydrogen atom or an alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group, each of which groups may optionally be substituted; or R2 itself represents a trifluoromethyl or an aroyl group; R3 represents a hydrogen atom or an alkyl, hydroxyalkyl, alkyl-O-R4 Ph, hydroxy, or O-R4, wherein R4 represents an alkyl group optionally substituted with an aryl group; R6 represents a hydrogen or halogen atom or a nitro, amino, acylamino, alkylsulfonylamino, alkylamino, dialkylamino, cyano, hydroxy, alkoxy or alkyl group; R7 represents a hydrogen atom or an alkoxy group; Y = e.g., CO, COO, CONH; Z represents a linear or branched chain alkylene group having from 1 to 6 carbon atoms and optionally having one hydroxy substituent; B = e.g., II, n = 1 or 2, A = substituted Ph, 2-pyrimidinyl; and their pharmaceutically acceptable salts useful for the treatment of **hypertension**, urethral and lower urinary tract contractions, and other disorders. The compds. are also useful for binding α1-adrenergic and 5HT1A serotonergic receptors, in vitro or in vivo. Thus, e.g., esterification of 8-carboxy-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran with 1-(3-chloropropyl)-4-(2-methoxyphenyl)piperazine followed by HCl treatment afforded 8-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propoxycarbonyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran dihydrochloride (III.2HCl) which exhibited IC50's of 20 and 19 nM, resp., for α1 and 5-HT1A receptor binding. Data were also presented for the effect of I on K+ stimulation of rat bladder strips, and on urethral contractions and blood pressure in dogs.

IT **152737-05-8P 152753-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyran derivs. having affinity for α1-adrenergic and

5HT1A-serotoninergic receptors)

RN 152737-05-8 HCAPLUS

CN Urea, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 152753-34-9 HCAPLUS

CN Urea, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152737-05-8

CMF C30 H32 N4 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S



IT **152737-74-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzopyran derivs. having affinity for α1-adrenergic and 5HT1A-serotoninergic receptors)

RN 152737-74-1 HCAPLUS
CN Urea, N-(2-chloroethyl)-N'-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)-(9CI) (CA INDEX NAME)



L18 ANSWER 44 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:969653 HCAPLUS
DOCUMENT NUMBER: 124:794
TITLE: Pharmaceutical preparations stimulating nitric oxide formation or release for prevention and treatment of endothelial dysfunction
INVENTOR(S): Noack, Eike Albrecht; Kojda, Georg
PATENT ASSIGNEE(S): Isis Pharma GmbH, Germany
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526725	A1	19951012	WO 1995-DE421	19950328 <--
W: AM, AU, BG, BR, BY, CA, CN, CZ, DE, EE, FI, GE, HU, IS, JP, KP, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 4410997	A1	19951026	DE 1994-4410997	19940330 <--
CA 2186783	AA	19951012	CA 1995-2186783	19950328 <--
AU 9521345	A1	19951023	AU 1995-21345	19950328 <--
AU 698359	B2	19981029		
EP 752858	A1	19970115	EP 1995-914275	19950328 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1150387	A	19970521	CN 1995-193401	19950328 <--
HU 76676	A2	19971028	HU 1996-2671	19950328 <--
HU 220165	B	20011128		
JP 09510979	T2	19971104	JP 1995-525343	19950328 <--
LV 11666	B	19970620	LV 1996-378	19960919 <--
FI 9603883	A	19960927	FI 1996-3883	19960927 <--
NO 9604102	A	19960927	NO 1996-4102	19960927 <--
US 5973011	A	19991026	US 1996-721465	19960927 <--
LT 4310	B	19980325	LT 1996-148	19961022 <--
BG 63073	B1	20010330	BG 1996-100930	19961022 <--
PRIORITY APPLN. INFO.:			DE 1994-4410997 A	19940330 <--
			WO 1995-DE421 W	19950328 <--

AB Compds. which release or transfer NO, endogenous NO formation stimulators, and guanylate cyclase stimulators are useful for preventing, treating, and

eliminating vascular endothelial dysfunction and associated diseases. The endothelial dysfunction may result from hypercholesteremia, hypoxia, mech. damage from angiog., reperfusion, **hypertension**, diabetic angiopathy, etc. Thus, pentaerythrityl tetranitrate (6 mg/kg/day in the feed) protected rabbits maintained on cholesterol-enriched feed from development of atherosclerotic lesions and from loss of the acetylcholine-induced, endothelium-mediated vasorelaxation response. Tablets were prepared containing pentaerythrityl tetranitrate 20, lactose 137, potato starch 80, gelatin 3, talc 22, Mg stearate 5, and highly disperse SiO2 6 mg.

IT **34262-84-5**, Mesocarb
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical prepns. stimulating nitric oxide formation or release for prevention and treatment of endothelial dysfunction)

RN 34262-84-5 HCAPLUS
CN 1,2,3-Oxadiazolium, 3-(1-methyl-2-phenylethyl)-5-[[(phenylamino)carbonyl]amino]-, inner salt (9CI) (CA INDEX NAME)



L18 ANSWER 45 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:828305 HCAPLUS
DOCUMENT NUMBER: 123:228915
TITLE: Preparation of biphenylyltetrazole-containing amino acid and dipeptide derivatives as angiotensin II antagonists
INVENTOR(S): Naka, Yoichi; Sonda, Shuji; Nakagawa, Haruto; Uehata, Masayoshi
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 07048360	A2	19950221	JP 1994-116464		19940530 <--
PRIORITY APPLN. INFO.:			JP 1994-116464	A	19940530 <--
			JP 1993-154348		19930531 <--

OTHER SOURCE(S): MARPAT 123:228915
GI



I



II

AB The title compds. [I; X = (un)substituted NH2, alkenyl, cycloalkyl, aryl, or heteroaryl, saturated carbocyclyl containing NR in the ring; wherein R = H, acyl, alkoxycarbonyl, aralkoxycarbonyl; Y1, Y2 = H, alkyl, alkenyl, cycloalkyl, halo, OR1, NHR1, CO2 R1, CONHR1, COR1, aryl, heteroaryl; or Y1Y2 = O, S; wherein R1 = H, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl; Z = CONH, CH2CONH, COCH2NH, COCH2CONH, single bond; when Z = CONH, A1A2 = cycloalkane ring optionally having a benzene ring-fused C5-7 substituent; when Z = CH2CONH, COCH2NH, COCH2CONH, or single bond, A1, A2 = H, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl or A1A2 = cycloalkane ring optionally having a benzene ring-fused C5-7 substituent], useful for the treatment of **hypertension**, ischemic heart failure, stroke, kidney diseases, and hypertrophy of the heart or blood vessels, are prepared Thus, H-Phe-OCH2Ph was alkylated by [2'-(triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl bromide in the presence of K2CO3 in DMF at room temperature for 24 h and then condensed with Z-Pro-Cl in aqueous NaHCO3/CH2Cl2 at room temperature for 3 h followed by deprotection with 2 N HCl/dioxane and hydrogenolysis over 10% Pd-C in EtOH-dioxane to give N-(S)-prolyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-(S)-phenylalanine. (RS)-(2-thienyl)alanine derivative (II) in vitro showed IC50 of 13 nM against angiotensin II in vascular smooth muscle cells of rat thoracic aorta.

IT **168466-35-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of biphenylyltetrazole-containing amino acid and dipeptide derivs. as angiotensin II antagonists)

RN 168466-35-1 HCAPLUS

CN L-Phenylalanine, N-[[[(propylamino)carbonyl]amino]carbonyl]-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 46 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:823093 HCAPLUS
DOCUMENT NUMBER: 123:228185
TITLE: Preparation of chloro(fluorophenyl)[[(dihydroimidazolonyl)ethyl]piperidinyl]indole 5-HT2 receptor antagonists
INVENTOR(S): Perregaard, Jens Kristian; Moltzen, Ejner Knud; Andersen, Kim; Pedersen, Henrik; Boegesoe, Klaus Peter; Pernet, Andre; Bopp, Barbara; Mulford, Darcy; Sakamoto, Kiyoshi
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9512591	A1	19950511	WO 1994-DK407	19941028 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 111394	A1	19980816	IL 1994-111394	19941025 <--
IL 111395	A1	19990620	IL 1994-111395	19941025 <--
CA 2175498	AA	19950511	CA 1994-2175498	19941028 <--
CA 2175498	C	20050726		
AU 9480577	A1	19950523	AU 1994-80577	19941028 <--
AU 683700	B2	19971120		
EP 726898	A1	19960821	EP 1994-931520	19941028 <--
EP 726898	B1	20001220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

CN 1134149	A	19961023	CN 1994-193987		19941028 <--
JP 09506083	T2	19970617	JP 1994-512968		19941028 <--
HU 76063	A2	19970630	HU 1996-1144		19941028 <--
PL 176391	B1	19990531	PL 1994-314181		19941028 <--
RU 2156249	C2	20000920	RU 1996-110902		19941028 <--
AT 198199	E	20010115	AT 1994-931520		19941028 <--
ES 2154303	T3	20010401	ES 1994-931520		19941028 <--
PT 726898	T	20010531	PT 1994-931520		19941028 <--
SK 281761	B6	20010710	SK 1996-534		19941028 <--
CZ 291403	B6	20030312	CZ 1996-1248		19941028 <--
ZA 9408589	A	19950626	ZA 1994-8589		19941101 <--
FI 9601844	A	19960430	FI 1996-1844		19960430 <--
NO 9601746	A	19960628	NO 1996-1746		19960430 <--
NO 309038	B1	20001204			
US 5703087	A	19971230	US 1996-635905		19961127 <--
HK 1013817	A1	20010713	HK 1998-115091		19981223 <--
GR 3035462	T3	20010531	GR 2001-400296		20010222 <--
LV 12805	B	20020520	LV 2001-178		20011220 <--
PRIORITY APPLN. INFO.:			DK 1993-1234	A	19931101 <--
			WO 1994-DK407	W	19941028 <--

OTHER SOURCE(S): MARPAT 123:228185
GI



I

AB The title compds. (I; R1-R4 = hydrogen, deuterium, halogen, alkyl, aryl, hydroxy, alkoxy, aryloxy, alkylthio, arylthio; R1 and R2 and/or R3 and R4 may constitute an oxo or thioxo group; R1 and R2 and/or R3 and R4 are joined together to form a 3-8 membered spiro ring; all 4 of R1-R4 ≠ H), which are non-cataleptogenic 5-HT2 receptor antagonists, useful in the treatment of psychosis, depression, neg. symptoms of schizophrenia, **hypertension**, or extrapyramidal side effects induced by antipsychotic drugs, are prepared and I-containing formulations presented. Thus, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl]ethyl]-5-hydroxyimidazolidin-2-one, m.p. 174-175°, prepared from glycine in 4 steps, demonstrated a IC50 against 3H-ketanserin binding to rat cortex 5-HT2 receptors of 1.4 nM.

IT **87219-18-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chloro(fluorophenyl)[[(dihydroimidazolonyl)ethyl]piperidinyl]indole 5-HT2 receptor antagonists from)
RN 87219-18-9 HCAPLUS
CN Glycine, N-[[(2-chloroethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 47 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:795411 HCAPLUS
DOCUMENT NUMBER: 124:29754
TITLE: Use of N-arylheteroarylalkyl imidazol-2-one compounds as angiotensin II antagonists for treatment of circulatory disorders
INVENTOR(S): Reitz, David B.; Manning, Robert E.
PATENT ASSIGNEE(S): G. D. Searle and Co., USA
SOURCE: U.S., 81 pp. Cont.-in-part of U.S.5,164,403.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5441970	A	19950815	US 1993-107742	19930819 <--
US 5164403	A	19921117	US 1991-681011	19910405 <--
WO 9217469	A2	19921015	WO 1992-US2439	19920401 <--
WO 9217469	A3	19921112		
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9219278	A1	19921102	AU 1992-19278	19920401 <--
EP 579766	A1	19940126	EP 1992-911354	19920401 <--
EP 579766	B1	19990602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5643906	A	19970701	US 1993-86959	19930701 <--
US 5861420	A	19990119	US 1997-784223	19970116 <--
US 6492397	B1	20021210	US 2000-616639	20000726 <--
PRIORITY APPLN. INFO.:			US 1991-681011	A2 19910405 <--
			WO 1992-US2439	W 19920401 <--
			US 1992-894032	B1 19920604 <--
			US 1995-460362	A3 19950602 <--
			US 1997-784223	A1 19970116 <--
			US 1998-196876	B1 19981120
			US 1999-417992	B1 19991013

OTHER SOURCE(S): MARPAT 124:29754
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A class of N-arylheteroarylalkyl imidazol-2-one compds. is described for

use in treatment of circulatory disorders such as **hypertension** and congestive heart failure. Compds. of particular interest are angiotensin II antagonists I where A is selected from II-VII, wherein m is one, R1 = e.g., alkyl, benzyl, cyclohexyl, benzoyl, 2-hydroxybutyl; R0 = H; R2 = e.g., alkyl, Ph, benzyl, alkylthio; wherein each of R3, R4, R6, R7, R8, R9, R10, R11 is H and R5 must be selected from, e.g., CO2H, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, tetrazolyl, triazolyl. Thus, e.g., coupling of 2-(trityltetrazol-5-yl)phenylboronic acid (preparation given) with 1,4-dibutyl-1,3-dihydro-3-[(6-bromo-3-pyridinyl)methyl]-2H-imidazol-2-one (preparation given) gave imidazolone VIII (43%) which exhibited angiotensin II receptor binding affinity IC50 = 6.5 nM.

IT **141387-84-0P 141405-47-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(use of N-arylheteroarylalkyl imidazol-2-one compds. as angiotensin II antagonists for treatment of circulatory disorders)

RN 141387-84-0 HCAPLUS
CN Urea, N-butyl-N'-[1-(5,5-dimethyl-1,3-dioxan-2-yl)pentyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141405-47-2 HCAPLUS
CN Hexanamide, 2-[[(butylamino)carbonyl]amino]-N-methoxy-N-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 48 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:608021 HCAPLUS
DOCUMENT NUMBER: 123:286014
TITLE: (Biphenylylmethyl)imidazopyridine derivatives bearing acidic functional groups as angiotensin II antagonists
INVENTOR(S): Chakravarty, Prasun K.; Greenlee, William J.; Kim, Dooseop; Mantlo, Nathan B.; Patchett, Arthur A.;

Rivero, Ralph A.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 71 pp. Cont.-in-part of U.S. Ser. No. 832,781, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5412097	A	19950502	US 1992-940267	19920902 <--
CA 2062558	AA	19920909	CA 1992-2062558	19920306 <--
JP 04327586	A2	19921117	JP 1992-50850	19920309 <--
JP 07025758	B4	19950322		

PRIORITY APPLN. INFO.: US 1991-666534 B2 19910308 <--
US 1992-832781 B2 19920214 <--

OTHER SOURCE(S): MARPAT 123:286014
GI



I

AB Heterocyclic compds. of structural formula: I [R1 = e.g., SO2NR24OR24, SO2NHSO2R23, SO2NHP(O)(R25)2; R2a and R2b are independently, e.g., H, halo, NO2, NH2; R3a = e.g., H, halo, C1-6-alkyl; R3b = e.g., H, halo, NO2, C1-6-alkyl; E = e.g., single bond, NR13(CH2)s, S(O)n wherein n is 0 to 2 and s is 0 to 5; R6 = e.g., C1-9-alkyl, perfluoro-C1-4-alkyl, C3-7-cycloalkyl; A-B-C-D represents, e.g., CR7:CR7CR7:N, N:CR7CR7:CR7, CR7:CR7N:CR7; X = e.g., C-C single bond, CO, O, S; R24 = e.g., H, aryl, C1-6-alkyl; R23 = e.g., aryl, heteroaryl, C3-4-cycloalkyl; R25 = e.g., aryl, C1-6-alkyl; R13 = e.g., H, CO(C1-4-alkyl), C1-6-alkyl; R7 groups can be the same or different and represent, e.g., H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl] are angiotensin II antagonists useful in the treatment of **hypertension** and congestive heart failure. Thus, e.g., alkylation of 5,7-dimethyl-2-ethylimidazo[4,5-b]pyridine with 4'-(bromomethyl)-N-tert-butylbiphenyl-2-sulfonamide afforded 60% 5,7-dimethyl-2-ethyl-3-[2'-[(tert-butylamino)sulfonyl](1,1'-biphenyl-4-yl)methyl]imidazo[4,5-b]pyridine;

deprotection afforded the 2'-aminosulfonyl derivative which gave the 2'-[(isopropylsulfonylamino)sulfonyl] derivative upon reaction with isopropylsulfonyl chloride. Representative compds. of the invention exhibited an angiotensin II antagonist activity of at least IC50 < 50 μM. Pharmaceutical formulations were given.

IT **169281-67-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((biphenylylmethyl)imidazopyridine derivs. bearing acidic functional groups as angiotensin II antagonists)

RN 169281-67-8 HCAPLUS

CN Carbamic acid, [[4'-[[6-[[(ethylamino)carbonyl]amino]-7-methyl-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-, butyl ester (9CI) (CA INDEX NAME)



IT **169281-66-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
((biphenylylmethyl)imidazopyridine derivs. bearing acidic functional groups as angiotensin II antagonists)

RN 169281-66-7 HCAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[[6-[[(ethylamino)carbonyl]amino]-7-methyl-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 49 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:580487 HCAPLUS
DOCUMENT NUMBER: 122:315099
TITLE: Preparation of peptides as novel endothelin antagonists

INVENTOR(S): Ishikawa, Kiyofumi; Fukami, Takehiro; Ihara, Masaki; Nishikibe, Masaru; Yano, Mitsuo
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9419368	A1	19940901	WO 1994-JP194		19940209 <--
W: AU, CA, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9460103	A1	19940914	AU 1994-60103		19940209 <--
JP 07041498	A2	19950210	JP 1994-35239		19940209 <--
PRIORITY APPLN. INFO.:			JP 1993-57814	A	19930223 <--
			JP 1993-144216	A	19930524 <--
			WO 1994-JP194	W	19940209 <--

OTHER SOURCE(S): MARPAT 122:315099
GI



I

AB Peptides represented by formula [I; R1O2C (wherein R1 = lower alkyl or aryl) or R21R22NCO (wherein R21 = lower alkyl, cycloalkyl, cycloalkylalkyl, adamantyl, or optionally substituted aryl or heteroaryl; R22 = H, lower optionally substituted by OH, cycloalkyl, cycloalkylalkyl or R21R22N = C4-8 5- to 9-membered ring N-containing saturated heterocyclyl wherein any methylene group not adjacent to the N atom may be replaced with S and any 1-4 H atoms on the heterocyclyl group may be independently substituted by lower alkyl or lower hydroxyalkyl or it may form a benzo-fused ring at two adjacent C atoms); R3 = H, lower alkyl; R4 = lower alkylthioalkyl, alkenyl, cycloalkyl or cycloalkyl-lower alkyl optionally substituted by C1-4 lower, alkyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl; X = halo, lower alkyl; R5 = H, lower alkyl; R6 = H, HO, lower alkoxy or alkylthio, lower alkyl or alkenyl optionally having aryl or heteroaryl substituent; n = 0,1; Y = CH2OH, CO2R71 (wherein R71 = H, lower alkyl), CONR72R73 (wherein R72, R73 = H, aryl, heteroaryl, lower alkyl optionally substituted with OH, CO2H, or SO3H), 1H-tetrazol-5-yl, SO3H, P(O)(OH)2] or analogs thereof are prepared These compds. I exhibit antagonism against reactions of an endothelin, one of the intrinsic, physiol. active peptides, via endothelin A and B receptors and hence are useful as a remedy for various diseases wherein the endothelin participates, including **hypertension**, pulmonary **hypertension**, Raynaud's disease, asthma, acute kidney failure, myocardial infarction, angina pectoris, etc. Thus, Nim-(tert-

butoxylcarbonyl)-2-chloro-D-tryptophyl-D-norleucine tert-Bu ester was condensed with N-2,6-dimethylpiperidinocarbonyl-L-valine by using 1-hydroxy-1H-benzotriazole hydrate and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 and deprotected with CF3CO2H at room temperature to give title compound I (A = Q, R3 = R5 = H, R4 = CHMe2, R6 = Bu, X = Cl, n = 0, Y = CO2H) (II). II and I (A = Q, R3 = R5 = H, R4 = CHMe2, R6 = n-Pr, X = Br, n = 0, Y = CO2H) at 1.1 μM in vitro inhibited 90 and 100%, resp., the binding of [125I]endothelin to endothelin receptor subtype-ETA preparation from pig aorta smooth muscle tissue and 99 and 100% resp., that to endothelin receptor subtype-ETB preparation from pig cerebellum.

IT **163445-85-0P 163445-86-1P 163445-87-2P**
163445-88-3P 163445-89-4P 163445-90-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as endothelin receptor antagonists)

RN 163445-85-0 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[[(2-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-86-1 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[[(2-methoxyphenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-87-2 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-88-3 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[(phenylamino)carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-89-4 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-

D-tryptophyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163445-90-7 HCAPLUS
CN D-Norleucine, N-[2-bromo-N-[N-[[(2-chlorophenyl)amino]carbonyl]-L-leucyl]-D-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 50 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:362667 HCAPLUS
DOCUMENT NUMBER: 122:282262
TITLE: Endothelin antagonist peptides
INVENTOR(S): Cody, Wayne L.; Depue, Patricia; Doherty, Annette M.; He, John X.; Taylor, Michael D.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 809, 746, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5382569	A	19950117	US 1992-995480	19921221 <--
CA 2108754	AA	19921117	CA 1992-2108754	19920424 <--
ES 2151888	T3	20010116	ES 1992-923584	19920424 <--
CA 2146874	AA	19940707	CA 1993-2146874	19931217 <--
WO 9414843	A1	19940707	WO 1993-US12377	19931217 <--
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9458280	A1	19940719	AU 1994-58280	19931217 <--
AU 679712	B2	19970710		
EP 675902	A1	19951011	EP 1994-904089	19931217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08504823	T2	19960528	JP 1993-515347	19931217 <--
JP 3494649	B2	20040209	JP 1994-515347	19931217 <--
US 5641752	A	19970624	US 1994-316533	19940930 <--
US 5773414	A	19980630	US 1997-813625	19970307 <--
PRIORITY APPLN. INFO.:			US 1991-701274 B2	19910516 <--
			US 1991-809746 B2	19911218 <--
			US 1992-995480 A	19921221 <--
			WO 1993-US12377 W	19931217 <--
			US 1994-316533 A3	19940930 <--

OTHER SOURCE(S): MARPAT 122:282262

AB Novel antagonist peptides (Markush included) of endothelin are described, as well as methods for the preparation and pharmaceutical compns. of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, **hypertension**, myocardial infarction, metabolic, endocrinol., neurol. disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary **hypertension**, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes. More than 300 specific peptides are claimed. Preparation of peptides is described, and activities (rat heart ventricle binding assay, inositol phosphate accumulation, arachidonic acid release assay) are included for selected peptides.

IT **160480-79-5 160480-80-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonist peptides for therapeutic use)

RN 160480-79-5 HCAPLUS

CN L-Tryptophan, N-[N-[N-[N-[N-[N-[(cyclohexylamino)carbonyl]-β-phenyl-D-phenylalanyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 160480-80-8 HCAPLUS
CN L-Tryptophan, N-[N-[N-[N-[N-[(methylamino)carbonyl]-β-phenyl-D-phenylalanyl]-L-leucyl]-L-α-aspartyl]-L-isoleucyl]-L-isoleucyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— NHMe

=> d ibib abs hitstr l18 1-50

L18 ANSWER 1 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:220036 HCAPLUS
DOCUMENT NUMBER: 140:247606
TITLE: Method to treat cardiac fibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist
INVENTOR(S): Egan, James J.; McMahon, Ellen G.; Olins, Gillian M.; Schuh, Joseph R.
PATENT ASSIGNEE(S): G.D. Searle & Co., USA
SOURCE: U.S. Pat. Appl. Publ., 146 pp., Cont.-in-part of U.S. Ser. No. 506,068, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004053903	A1	20040318	US 2003-371699	20030221 <--
PRIORITY APPLN. INFO.:			US 1997-783404	B1 19970113 <--
			US 1997-980734	B3 19971201 <--
			US 1998-181586	B1 19981028
			US 1999-317237	B1 19990524
			US 2000-506068	B1 20000217

OTHER SOURCE(S): MARPAT 140:247606
AB A therapeutic method is described for treating cardiac fibrosis or cardiac hypertrophy using a combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of an angiotensin II receptor antagonist. Preferred angiotensin II receptor antagonists are those compds. having high potency and bioavailability and which are characterized in having an imidazole or triazole moiety attached to a biphenylmethyl or pyridinyl/phenylmethyl moiety. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compds. characterized by the presence of a 9α, 11α-substituted epoxy moiety. A preferred combination therapy includes the angiotensin II receptor antagonist 5-2-[5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-pyridinyl]phenyl-1H-tetrazole and the aldosterone receptor antagonist epoxymexrenone.
IT **133085-33-3**, BIBS39
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method to treat cardiac fibrosis and hypertrophy with a combination therapy of an angiotensin II (AngII) antagonist and an epoxy-steroidal aldosterone antagonist)
RN 133085-33-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[2-butyl-6-[[(cyclohexylamino)carbonyl]amino]-1H-benzimidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 158 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:197917 HCAPLUS
DOCUMENT NUMBER: 138:231736
TITLE: Inhibitors of epoxide hydrolases for the treatment of **hypertension**
INVENTOR(S): Kroetz, Deanna L.; Zeldin, Darryl C.; Hammock, Bruce D.; Morisseau, Christophe
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: U.S., 36 pp., Cont.-in-part of U.S. 6,150,415.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531506	B1	20030311	US 2000-721261	20001121 <--
US 5955496	A	19990921	US 1997-909523	19970812
US 6150415	A	20001121	US 1999-252148	19990218 <--
US 2003119900	A1	20030626	US 2002-328495	20021223
US 6693130	B2	20040217		
US 2004092487	A1	20040513	US 2003-694641	20031027

PRIORITY APPLN. INFO.:

US 1996-23397P	P	19960813 <--
US 1997-909523	A2	19970812 <--
US 1999-252148	A2	19990218
US 2000-721261	A1	20001121
US 2002-328495	A1	20021223

OTHER SOURCE(S): MARPAT 138:231736
GI



I

AB The invention provides compds. that inhibit epoxide hydrolase in therapeutic applications for the treatment of **hypertension**. A preferred class of compds. for practicing the invention have the structure shown by Formula [(R1)(R2)XW(Z)Y(R3)(R4)], wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present

when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

IT **101-20-2 886-59-9 1142-07-0 1145-53-5**
1220-01-5 2222-58-4 2387-23-7
4300-43-0 13074-28-7 13256-78-5
17661-70-0 25855-24-7 29559-44-2
34583-53-4 38652-23-2 58490-15-6
60392-17-8 60392-18-9 62972-70-7
70243-17-3 70622-91-2 72802-45-0
72802-46-1 75461-45-9 80251-18-9
89609-46-1 92373-98-3 101452-64-6
108195-84-2 109246-29-9 111681-31-3
118389-04-1 120615-85-2 124949-24-2
128276-09-5 131519-56-7 148806-83-1
148806-87-5 158072-24-3 179539-07-2
195451-88-8 196791-88-5 197357-33-8
197455-83-7 200058-85-1 200059-00-3
246165-79-7 272449-13-5 287185-28-8
287185-29-9 303092-06-0 306770-63-8
306770-65-0 306770-66-1 306770-67-2
306770-68-3 306770-69-4 306770-70-7
306770-71-8 326003-50-3 338797-32-3
338797-34-5 339170-08-0 392713-22-3
400839-30-7 401598-13-8 402939-18-8
446848-38-0 447429-19-8 460745-85-1
479413-00-8 479413-14-4 479413-19-9
479413-39-3 479413-45-1 479413-68-8
501003-77-6 501003-78-7 501003-79-8
501003-80-1 501003-81-2 501003-82-3
501003-83-4 501003-84-5 501003-85-6
501003-86-7 501003-87-8 501003-88-9
501003-89-0 501003-90-3 501003-91-4
501003-92-5 501003-93-6 501003-94-7
501003-95-8 501003-96-9 501003-97-0
501003-98-1 501003-99-2 501004-00-8
501004-01-9 501004-02-0 501004-03-1
501004-04-2 501004-05-3 501004-06-4
501004-07-5 501004-08-6 501004-09-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epoxide hydrolases inhibitors for treatment of **hypertension**)

RN 101-20-2 HCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 886-59-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 1142-07-0 HCAPLUS
CN Urea, N-hexyl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 1145-53-5 HCAPLUS
CN Urea, N-cycloheptyl-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 1220-01-5 HCAPLUS
CN Urea, N-cyclohexyl-N'-cyclooctyl- (9CI) (CA INDEX NAME)



RN 2222-58-4 HCAPLUS
CN Urea, N-cyclohexyl-N'-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)



RN 2387-23-7 HCAPLUS
CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RN 4300-43-0 HCAPLUS
CN Urea, N,N'-bis(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 13074-28-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 13256-78-5 HCAPLUS
CN Urea, N-1-naphthalenyl-N'-propyl- (9CI) (CA INDEX NAME)



RN 17661-70-0 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 25855-24-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 29559-44-2 HCAPLUS
CN Urea, N,N'-bis(tricyclo[3.3.1.13,7]dec-1-yl)- (9CI) (CA INDEX NAME)



RN 34583-53-4 HCAPLUS
CN Urea, N-octyl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 38652-23-2 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 58490-15-6 HCAPLUS
CN Urea, N-cyclohexyl-N'-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 60392-17-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 60392-18-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 62972-70-7 HCAPLUS
CN Urea, N-(4-aminophenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 70243-17-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 70622-91-2 HCAPLUS
CN Urea, N-phenyl-N'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 72802-45-0 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 72802-46-1 HCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 75461-45-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 80251-18-9 HCAPLUS
CN Urea, N-butyl-N'-undecyl- (9CI) (CA INDEX NAME)



RN 89609-46-1 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 92373-98-3 HCAPLUS
CN Urea, N-(cyclohexylmethyl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 101452-64-6 HCAPLUS
CN Urea, N-cyclohexyl-N'-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)



RN 108195-84-2 HCAPLUS
CN Urea, N-cyclohexyl-N'-(6-hydroxyhexyl)- (9CI) (CA INDEX NAME)



RN 109246-29-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 111681-31-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 118389-04-1 HCAPLUS
CN Urea, N-butyl-N'-dodecyl- (9CI) (CA INDEX NAME)



RN 120615-85-2 HCAPLUS
CN Urea, N-tricyclo[3.3.1.13,7]dec-1-yl-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 124949-24-2 HCAPLUS
CN Urea, N-cyclohexyl-N'-cyclopentyl- (9CI) (CA INDEX NAME)



RN 128276-09-5 HCAPLUS
CN Urea, N-octyl-N'-propyl- (9CI) (CA INDEX NAME)



RN 131519-56-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 148806-83-1 HCAPLUS
CN Urea, N-cyclohexyl-N'-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 148806-87-5 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 158072-24-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 179539-07-2 HCAPLUS
CN Urea, N-cyclohexyl-N'-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 195451-88-8 HCAPLUS
CN Urea, N-(4-bromophenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 196791-88-5 HCAPLUS
CN Urea, N-[(4-chlorophenyl)methyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 197357-33-8 HCAPLUS
CN Urea, N-(cyclohexylmethyl)-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 197455-83-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 200058-85-1 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 200059-00-3 HCAPLUS

CN Urea, N-cyclohexyl-N'-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 246165-79-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 272449-13-5 HCAPLUS
CN Urea, N-(2-phenylethyl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 287185-28-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-decyl- (9CI) (CA INDEX NAME)



RN 287185-29-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 303092-06-0 HCAPLUS
CN Urea, N-cyclohexyl-N'-heptyl- (9CI) (CA INDEX NAME)



RN 306770-63-8 HCAPLUS
CN Urea, N-octyl-N'-pentyl- (9CI) (CA INDEX NAME)



RN 306770-65-0 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 306770-66-1 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-(4,4-diethoxybutyl)- (9CI) (CA INDEX NAME)



RN 306770-67-2 HCAPLUS
CN Urea, N-cyclohexyl-N'-octyl- (9CI) (CA INDEX NAME)



RN 306770-68-3 HCAPLUS
CN Urea, N-(cyclohexylmethyl)-N'-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 306770-69-4 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-decyl- (9CI) (CA INDEX NAME)



RN 306770-70-7 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)



RN 306770-71-8 HCAPLUS
CN Urea, N-(cyclohexylmethyl)-N'-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 326003-50-3 HCAPLUS
CN Benzamide, 4-chloro-N-[(cyclohexylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 338797-32-3 HCAPLUS
CN Urea, N-(1-methylethyl)-N'-octyl- (9CI) (CA INDEX NAME)



RN 338797-34-5 HCAPLUS
CN Urea, N-cyclobutyl-N'-octyl- (9CI) (CA INDEX NAME)



RN 339170-08-0 HCAPLUS
CN Urea, N-decyl-N'-phenyl- (9CI) (CA INDEX NAME)



RN 392713-22-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-hexylphenyl)- (9CI) (CA INDEX NAME)



RN 400839-30-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-pentyl- (9CI) (CA INDEX NAME)



RN 401598-13-8 HCAPLUS
CN Urea, N-[2-(1-cyclohexen-1-yl)ethyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 402939-18-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



RN 446848-38-0 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-hexyl- (9CI) (CA INDEX NAME)



RN 447429-19-8 HCAPLUS
CN Urea, N-cyclododecyl-N'-propyl- (9CI) (CA INDEX NAME)



RN 460745-85-1 HCAPLUS
CN Urea, N-dodecyl-N'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 479413-00-8 HCAPLUS
CN Urea, N-cyclododecyl-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 479413-14-4 HCAPLUS
CN Urea, N-cyclododecyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 479413-19-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 479413-39-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 479413-45-1 HCAPLUS
CN Urea, N-cyclohexyl-N'-hexyl- (9CI) (CA INDEX NAME)



RN 479413-68-8 HCAPLUS
CN Dodecanoic acid, 12-[[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 501003-77-6 HCAPLUS
CN Urea, N-(1,1,3,3-tetramethylbutyl)-N'-tricyclo[3.3.1.13,7]dec-2-yl- (9CI) (CA INDEX NAME)



RN 501003-78-7 HCAPLUS
CN Urea, N-hexyl-N'-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 501003-79-8 HCAPLUS
CN Urea, N-hexyl-N'-octyl- (9CI) (CA INDEX NAME)



RN 501003-80-1 HCAPLUS
CN Urea, N-(3-chlorophenyl)-N'-octyl- (9CI) (CA INDEX NAME)



RN 501003-81-2 HCAPLUS
CN Urea, N-nonyl-N'-propyl- (9CI) (CA INDEX NAME)



RN 501003-82-3 HCAPLUS
CN Urea, N-(1,1-dimethylpropyl)-N'-dodecyl- (9CI) (CA INDEX NAME)



RN 501003-83-4 HCAPLUS
CN Urea, N-cyclobutyl-N'-dodecyl- (9CI) (CA INDEX NAME)



RN 501003-84-5 HCAPLUS
CN Carbamic acid, [2-[[(cyclohexylamino)carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 501003-85-6 HCAPLUS
CN Urea, N-cyclohexyl-N'-nonyl- (9CI) (CA INDEX NAME)



RN 501003-86-7 HCAPLUS
CN Urea, N-cyclohexyl-N'-tridecyl- (9CI) (CA INDEX NAME)



RN 501003-87-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-tetradecyl- (9CI) (CA INDEX NAME)



RN 501003-88-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)



RN 501003-89-0 HCAPLUS
CN Urea, N-cyclohexyl-N'-(2-cyclohexylethyl)- (9CI) (CA INDEX NAME)



RN 501003-90-3 HCAPLUS
CN Urea, N-cyclohexyl-N'-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 501003-91-4 HCAPLUS
CN Urea, N-cyclohexyl-N'-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 501003-92-5 HCAPLUS
CN Urea, N-cyclohexyl-N'-[2-(phenylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 501003-93-6 HCAPLUS
CN Urea, N-cyclohexyl-N'-[4-(1,1-dimethylethyl)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 501003-94-7 HCAPLUS
CN Urea, N-bicyclo[2.2.1]hept-2-yl-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 501003-95-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-(1-tricyclo[3.3.1.13,7]dec-2-ylethyl)- (9CI) (CA INDEX NAME)



RN 501003-96-9 HCAPLUS
CN Urea, N-cyclohexyl-N'-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 501003-97-0 HCAPLUS
CN Urea, N-(cyclohexylmethyl)-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 501003-98-1 HCAPLUS
CN Urea, N-cyclohexyl-N'-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 501003-99-2 HCAPLUS
CN Urea, N-9-acridinyl-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 501004-00-8 HCAPLUS
CN Urea, N-cyclohexyl-N'-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 501004-01-9 HCAPLUS
CN Urea, N-(4-cyanophenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 501004-02-0 HCAPLUS
CN Urea, N-(4-acetylphenyl)-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 501004-03-1 HCAPLUS
CN Urea, N-(4-aminophenyl)-N'-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)



RN 501004-04-2 HCAPLUS
CN Urea, N-(3-phenylpropyl)-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 501004-05-3 HCAPLUS
CN Urea, N-[2-(1-cyclohexen-1-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 501004-06-4 HCAPLUS
CN Urea, N-(2,2-diethoxyethyl)-N'-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 501004-07-5 HCAPLUS
CN Urea, N-[4-(1-methylethyl)phenyl]-N'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 501004-08-6 HCAPLUS
CN Urea, N-hexyl-N'-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



D his ful #2 - Claim 15


```
=> d his ful

     (FILE 'HOME' ENTERED AT 10:33:33 ON 05 DEC 2005)

     FILE 'HCAPLUS' ENTERED AT 10:33:44 ON 05 DEC 2005
               ACT KWO641L35/L
              ---------
L1             STR
              ---------
               DIS

     FILE 'REGISTRY' ENTERED AT 10:34:25 ON 05 DEC 2005
L2             STR L1
L3          50 SEA SSS SAM L2
L4      339429 SEA SSS FUL L2
L5             STR L2
L6          50 SEA SSS SAM L5
L7      328696 SEA SSS FUL L5
L8             STR L2
L9          50 SEA SSS SAM L8
L10     211534 SEA SSS FUL L8

     FILE 'HCAPLUS' ENTERED AT 10:45:23 ON 05 DEC 2005
L11       351 SEA ABB=ON  L10 AND (HYPERTENSION+ALL OR HYPERTENSIVE AGENTS+AL
               L)

     FILE 'REGISTRY' ENTERED AT 10:47:31 ON 05 DEC 2005
L12            STR L8
L13         50 SEA SSS SAM L12
L14     117587 SEA SSS FUL L12

     FILE 'HCAPLUS' ENTERED AT 10:48:26 ON 05 DEC 2005
L15      18692 SEA ABB=ON  L14
L16         96 SEA ABB=ON  L15 AND (HYPERTENSION+ALL OR HYPERTENSIVE AGENTS+AL
               L)
L17        406 SEA ABB=ON  L11 OR L16

     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 5 Dec 2005  VOL 143 ISS 24
     FILE LAST UPDATED: 4 Dec 2005  (20051204/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.
```

Printed 1st 50 abs, per examiner request. See d que stat for Claim 15, attached.

As I mentioned during our phonecall, I did not search as fully since there were so many hits.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6
DICTIONARY FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> d que stat l30
L1         75361 SEA FILE=HCAPLUS ABB=ON  HYPERTENSION+ALL OR HYPERTENSIVE
                 AGENTS+ALL
L2            33 SEA FILE=HCAPLUS ABB=ON  L1 AND ?EPOXIDE?(W)?HYDROLASE?
L8                STR
```




```
VAR G1=6/8
NODE ATTRIBUTES:
NSPEC   IS RC     AT  10
NSPEC   IS RC     AT  11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L11        6521 SEA FILE=REGISTRY SSS FUL L8
L12           1 SEA FILE=HCAPLUS ABB=ON  L2 AND L11
L28           6 SEA FILE=HCAPLUS ABB=ON  L1 AND L11
L29           4 SEA FILE=HCAPLUS ABB=ON  L28 AND (PRD<19980208 OR PD<19980208)
L30           4 SEA FILE=HCAPLUS ABB=ON  L12 OR L29
```

Claim 15


```
=> d que stat l18
L8                  STR
```



Because of overflow in Registry, I had to search "O" and "S" separately.

```
VAR G3=AK/CY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L10       211534 SEA FILE=REGISTRY SSS FUL L8
L11          351 SEA FILE=HCAPLUS ABB=ON  L10 AND (HYPERTENSION+ALL OR HYPERTENS
                 IVE AGENTS+ALL)
L12                 STR
```




```
VAR G3=AK/CY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L14       117587 SEA FILE=REGISTRY SSS FUL L12
L15        18692 SEA FILE=HCAPLUS ABB=ON  L14
L16           96 SEA FILE=HCAPLUS ABB=ON  L15 AND (HYPERTENSION+ALL OR HYPERTENS
                 IVE AGENTS+ALL)
L17          406 SEA FILE=HCAPLUS ABB=ON  L11 OR L16
L18          158 SEA FILE=HCAPLUS ABB=ON  L17 AND (PRD<19980208 OR PD<19980208)


=> d que stat l11
L8                  STR
```




```
VAR G3=AK/CY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
```

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L10 211534 SEA FILE=REGISTRY SSS FUL L8
L11 351 SEA FILE=HCAPLUS ABB=ON L10 AND (HYPERTENSION+ALL OR HYPERTENS
IVE AGENTS+ALL)